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Abstract 
Network Meta-analysis of randomized control trials - A methodological perspective 
Objective The aim of this thesis was to explore methodological aspects related to network 
meta-analysis, especially in oncology field. For the purposes of this analysis, Small Cell Lung 
Cancer (SCLC) was used as an example, where the combination of Cisplatin plus Etoposide 
(EP) is currently the standard treatment. 
Methods PubMed, EMBASE and Cochrane Central Register of Controlled Trials were 
systematically searched to identify all RCTs that compared treatments for SCLC. Then, 
effectiveness of the treatments relative to the combination of Cisplatin plus Etoposide, 
reference treatment) was estimated by performing a network of treatments analysis, using 
both Bayesian and frequentist approaches. 
Results We identified 71 articles eligible for inclusion, involving 91 different treatments. In 
total, 16,026 patients were included in the analysis. Frequentist analysis (direct) revealed 
combination of Cisplatin plus Cyclophosphamide plus Etoposide plus Epirubicin showed 
better response than EP for the ORR outcome, but with worse tolerability. Indirect analysis 
revealed that the combination of Cisplatin plus Doxorubicin plus Etoposide (plus 
Vincrisitine) showed better response that EP for the ORR outcome. Bayesian analysis 
revealed that the combination of carboplatin or cisplatin plus etoposide with granulocyte-
colony stimulating factor (GCSF) provides higher probability of achieving ORR compared to 
other treatments. 
Conclusions The results should be interpreted with caution because the network was 
dominated by indirect comparisons. Large scale head-to-head RCTs are needed to confirm 
the present findings. Bayesian and frequentist approaches should be considered 
complementary tools in the clinical evaluator's toolkit. 
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Glossary 
Adjusted indirect comparison A statistical technique that permits comparison between two 
interventions that have not been compared directly (head-to- 
head) but have both been compared to the same third 
comparator. This method is preserves the principle of 
randomization. 
Bayesian analysis A statistical method that employs prior knowledge combined 
with data. 
Closed loop A network of 3 comparisons, each of which has been 
compared directly with the others. 
Consistency or coherence:
  
The manifestation of transitivity in the data from a network 
of interventions. It exists when treatment effects from direct 
and indirect evidence are in agreement (subject to the usual 
variation due to heterogeneity in the direct evidence). Unlike 
transitivity, consistency can be evaluated statistically. 
(In)coherence The (dis)agreement in treatment effect estimates between 
direct and indirect evidence. 
Co-occurrence The over-representation of RCTs comparing specific 
interventions rather than other available interventions. 
Credible intervals Bayesian analogy to confidence intervals 
Direct (head-to-head) 
evidence 
Data from RCTs that have compared interventions against 
each other. 
Diversity of a network A measure of how many treatments are available and whether 
they are equally represented or not across the network 
Fixed effects analysis A method of analysis that assumes that treatment effects are 
the same across all included trials 
Frequentist analysis A statistical approach that places the emphasis on available 
data (conventional approach to statistical analysis, contrast 
with Bayesian). 
Geometry of a network A graphical representation of the distribution of treatments 
and their comparisons across the network 
Heterogeneity The extent of inconsistency of treatment effects in a pairwise 
meta-analysis. 
Homogeneity The inverse of heterogeneity 
Inconsistent loop A closed loop in which treatment effect estimates from direct 
and indirect evidence are in statistically significant 
disagreement. 
Indirect evidence Evidence bearing on the relative effect of treatments that that 
have not been compared directly against each other but have 
a common comparator. Indirect evidence may be evaluated 
using accepted statistical approaches, including adjusted 
indirect comparisons and MTCs. 
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Lumley model of network 
meta-analysis 
A frequentist method for MTCs. 
Meta-regression A regression in which the dependent variable is the 
magnitude of treatment effect in individual studies and the 
independent variable are study characteristics. It is used to 
see if study characteristics can explain differences in 
magnitude of treatment effect across studies. 
Network meta-analysis Synthesis of information over a network of comparisons to 
assess the comparative effectiveness of more than 2 
alternative treatment options for the same condition. The 
method relies on mixed comparison and synthesizes direct 
and indirect evidence over the entire network to obtain the 
relative treatment effects for all comparisons and a ranking of 
the treatments.  
ORR ORR is defined as the proportion of patients with tumor size 
reduction of a predefined amount and for a minimum time 
period. Response duration usually is measured from the time 
of initial response until documented tumor progression. 
According to FDA, ORR is defined as the sum of partial 
responses plus complete responses. When defined in this 
manner, ORR is a direct measure of drug antitumor activity.  
OS Overall survival is defined as the time from randomization 
until death from any cause, and is measured in the intent-to-
treat population. Survival is considered the most reliable 
cancer endpoint, and when studies can be conducted to 
adequately assess survival, it is usually the preferred 
endpoint. 
PFS Progression-free survival (PFS) is defined as the time from 
random assignment in a clinical trial to disease progression or 
death from any cause, , and is measured in the intent-to-treat 
population 
Priors (informed) The representation of external (prior) knowledge about the 
intervention effects or degree of heterogeneity that is 
incorporated in Bayesian analysis. 
Priors (non-informative) In Bayesian analysis, the assumption that nothing is known 
about the intervention effect or degree of heterogeneity prior 
to looking at the available data 
Posterior distribution In Bayesian analysis, the probability distribution obtained by 
mixing prior knowledge with data 
Random effects analysis 
 
 
A method of analysis that incorporates variation between 
trials and allows the treatment effect to vary across the 
included trials. 
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Similarity A principle that all the trials are broadly similar with respect 
to populations, trial design and outcomes. Used 
interchangeably with the more statistical term 
“exchangeability.” 
 
Star Network 
A network where all treatments have been compared with a 
common comparator treatment but not between themselves. 
Statistical evaluation of consistency is impossible in a star 
network. 
Treatment rankings Ordering of treatments according to decreasing probability 
that they can produce better outcomes than competing 
interventions 
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Abbreviations 
ASCO American Society of Clinical Oncology 
CI Confidence Interval 
CR Complete Response 
ECOG Eastern Cooperative Oncology Group 
ED Extensive-Stage Disease 
ESMO European Society for Medical Oncology 
FDA Food and Drug Administration 
FE Fixed Effects 
HR Hazard Ratio 
LD Limited-Stage Disease 
MA Meta-Analyses 
MR Meta Regression 
mo(s). Month(s) 
N Number 
NCI National Cancer Institute 
NMA Network Meta-Analyses 
OR Odds Ratio 
ORR Overall Response Rate 
OS Overall Survival 
PFS Progression-Free Survival 
RCT Randomized Controlled Trials 
Q Heterogeneity Statistic 
QoL Quality of  Life 
PR Partial Response 
RCT Randomized Controlled Trial 
RD Risk Difference 
RE Random Effects 
RR Risk Ratio 
SCLC Small Cell Lung Cancer 
SD Stable Disease 
SE Standard Error 
SUCRA Surface Under the Cumulative Ranking 
WHO World Health Organization 
wk(s) Week(s) 
yr(s) Year(s) 
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Chapter 1 - Overview of Network Meta-Analysis 
 
1.1 Introduction 
Meta-analysis is a statistical technique to synthesize information from a collection of all 
relevant studies comparing the same intervention for a medical condition of interest to 
address a focused research question in the context of a systematic review [1, 2]. Systematic 
reviews and meta-analyses of randomized controlled trials (RCTs) are fundamental tools for 
the clinical practice and are placed at the peak of evidence based medicine pyramid, 
influencing significantly the decision making of clinicians, scientists and policy makers. 
When conducted well, and transparently reported, systematic reviews and meta-analyses 
produce information that can be helpful for the evaluation of healthcare interventions.  
However, a potential drawback of traditional meta-analyses is their ability to compare only 
two interventions a time, a significant obstacle for decision-making when the medical 
condition under study has many relevant treatment options to be considered in clinical 
practice [3–8].  
Moreover, in situations where there are no studies directly comparing two or more 
interventions, traditional meta-analysis cannot estimate their comparative benefits and harms. 
A simple example of this scenario is when information from RCTs is available regarding the 
effectiveness of two active treatments, generically “A” and “B”, in comparison to a common 
comparator “C” (commonly placebo or standard of care practice); an indirect treatment 
comparison may be used to estimate a comparison of the relative effectiveness of “A” 
compared with “B” (Figure 1). 
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Figure 1: Direct evidence comes from the synthesis of trials of A versus B. Indirect 
evidence comes through an intermediate/common comparator C (many intermediate 
comparators are possible) by combining trials of A versus C and of C versus B (prior to 
combination the trials were synthesized). 
 
In that case, an indirect comparison of “A” versus “B” can be obtained by synthesizing the 
results of the trials providing information on the direct comparisons of “A” versus “C” and 
“C” versus “B”, by means of so-called network meta-analysis (NMA).  
NMA also allows for the combination of direct and indirect information in the estimation of a 
single treatment effect, which has come to be known as a mixed comparison. In this example, 
the mixed comparison between “A” and “B” incorporates the results of the direct comparison 
of the two treatments (i.e., outcome data from RCTs of “A” vs. “B”) with indirect 
comparison results obtained from the information of other related direct comparisons (i.e., 
outcome data from RCTs of “A” vs. “C” and “C” vs. “A”). 
In practice, mixed comparisons can be estimated as a weighted average of the direct and 
indirect estimates of treatment effects, and they can complement information for those 
comparisons in which there is scarce direct information. Both direct and indirect evidence 
contribute to the total body of evidence. Statistical methods for comparing multiple 
interventions (using a Bayesian or frequentist framework) have been described extensively in 
the literature [9–12]. 
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1.2 Attractiveness of NMA  
Network meta-analysis (NMA) is becoming increasingly popular for evidence synthesis [13–
16] and is evolving to the ‘new norm’ for comparative effectiveness research [17, 18]. Most 
recently, Petropoulou et al identified 456 NMAs being published between 1999 and 2015 by 
searching three bibliographic databases and assessed the characteristics of their statistical 
analysis and reporting of results [18].  Between 1999 and 2004 only 6 NMAs were published 
(1 in 1999, 2 in 2000, 1 in 2003 and 2 in 2004). The number of NMAs published per year 
after 2004 is presented in Table 1. It is evident that the number of published studies applying 
NMA methods to clinical research questions has been increasing significantly over the last 
two decades (p=0.04). [18] 
 
Table 1: Networks published between 2005 and 2014  
2005 2006 2007 2008 2009 2010 2011 2012 2013 2014 
6 12 9 12 27 30 53 59 96 103 
 
The quality and transparency of reporting also increased: in recent years around 90% of 
articles clearly reported whether a random-effects or fixed-effect model was used, and in 
2015 all reports included a description of the statistical methods used. It should be noted that 
the Bayesian hierarchical model remained the most popular approach for NMA during the 
study period: only five articles reported the use of frequentist multivariate meta-analysis or 
meta-regression [Figure 2]. 
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Figure 2: Methods used to synthesize the data in relation to the shape of the network 
[18]  
 
 
We performed a similar analysis focusing only on oncology studies [Appendix Table 1] and a 
similar effect was observed [Table 2].  
Specifically there is a significant increase of NMAs in oncology/hematology after 2010, 
reaching up to 25% of the total NMA reported in 2014. 
 
Table 2: Networks in Oncology published between 2005 and 2014 
2005 2006 2007 2008 2009 2010 2011 2012 2013 2014 
0/6 1/12 1/9 2/12 4/27 0/30 5/53 8/59 14/96 24/103 
Note: Literature Research String: (network OR mixed treatment* OR multiple treatment* OR mixed 
comparison* OR indirect comparison* OR umbrella OR simultaneous comparison*) AND (meta-
analysis) AND (oncology); Literature Research Timelines: up to April 14, 2015 
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In the lack of many direct comparisons, NMA is anticipated to play a key role in evaluating 
established treatments but also comparing innovative treatments to standard of care. 
For the purposes of this exercise, Small Cell Lung Cancer was selected as a setting to explore 
methodological perspective for NMAs 
 
1.3 Rationale for the research 
The aim of this thesis is to explore methodological aspects related to network meta-analysis, 
especially in oncology field. For the purposes of this analysis, SCLC will be used as an 
example. 
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Chapter 2 – Methodological consideration for network 
meta-analyses 
 
2.1 Assumptions and validity considerations: transitivity and consistency 
The validity of a NMA depends on a set of assumptions. The main assumption, which 
supports the validity of indirect and mixed comparison, is that there are no important 
differences between the trials making different comparisons other than the treatments being 
compared.  
This assumption has been described alongside several terms in the literature, including 
similarity (19, 20), transitivity (4, 21), consistency (22), and coherence (11). These core 
assumptions for NMAs can be verified conceptually and epidemiologically but are, however, 
subject to substantial uncertainty.  
2.1.2 Transitivity and Similarity 
The synthesis of studies making a direct comparison of two treatments is meaningful only 
when the studies are sufficiently similar in terms of key clinical and methodological 
characteristics (which are known as effect modifiers). The effect modifiers are not necessary 
to be identical; however heterogeneity of effects across studies should be acceptable. A valid 
indirect comparison (such as A versus B) requires that the sets of A versus C and B versus C 
studies are similar in their distributions of effect modifiers (for example, population 
characteristics, disease stage at baseline, treatment dose, sample size, and study quality). In 
that case we assume that the intervention effects are transitive. Transitivity can be viewed as 
the extension of clinical and methodological homogeneity to comparisons across groups of 
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studies that compare treatments. In complex network structures, the transitivity assumption 
should hold for all cases where indirect or mixed estimates are derived.  
For example, let’s assume that all A versus C studies include patients with Extended-Stage 
Disease and all BC studies include patients with Limited-Stage Disease. Each study set is 
similar within itself (at least according to this particular characteristic), but the two study sets 
deal with clinically different populations. So, if severity is an effect modifier, the transitivity 
assumption would not hold, and synthesis of these two meta-analyses would not give a valid 
A versus B estimate (21). 
A special case of an effect modifier that can vary across comparisons violating the transitivity 
assumption is the nature of the common comparator. If comparator C is systematically 
different in A versus C and B versus C studies (for example, treatment C is administered as 
an oral tablet in A versus C studies but as a different formulation in B versus C studies), then 
the transitivity assumption probably might not hold, and the indirect comparison between 
treatments A and B might not be valid.  
The plausibility of the transitivity assumption requires clinical judgment to decide whether 
differences in the distributions of the effect modifiers across studies are significant enough to 
make network meta-analysis invalid.  If an imbalanced distribution of effect modifiers is 
identified, adjustment can be used to improve transitivity through network meta-regression 
(23, 24). Adjustment should take place only for study or patient characteristics that are effect 
modifiers (such as severity of illness at baseline, number of previous episodes, age, or 
gender) (25). 
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2.1.2 Consistency 
Consistency (or coherence) is the statistical manifestation of transitivity and occurs when the 
subtraction equation is supported by the data. It can be evaluated only when a loop in the 
evidence network exists, that is, when there is direct and indirect evidence for a particular 
comparison of interventions. The distinction between transitivity and consistency is 
analogous to the distinction between clinical or methodological heterogeneity and statistical 
heterogeneity seen in standard meta-analysis:  
• Heterogeneity refers to the degree of disagreement between study-specific treatment 
effects and is measured by differences in estimates of study treatment effect beyond 
what chance can explain.  
• Inconsistency refers to the degree of disagreement between source-specific (and not 
study-specific) treatment effects and is measured by differences between direct and 
indirect estimates beyond what chance can explain (4).  
Heterogeneity is usually evaluated by the Cochran Q test or the I2 statistic (26). Consistency 
in a network meta-analysis can be evaluated statistically by comparing the direct and indirect 
summary effects in specific loops (10, 11) or across a network by fitting models that allow 
and do not allow for inconsistency (22, 27, 28).  
 
2.2 Network Geometry 
In principle, the graphical representation of a network, showing the multiple competing 
treatments, supports the understanding and the assessment of the strength of the clinical 
evidence for each of the various comparisons under study. It also improves the transparency 
of the results of a NMA from the perspective of determining the degree of confidence one 
may place in interpreting particular comparisons. Network geometry addresses what the 
shape of the treatment network looks like in terms of the number of included interventions 
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(i.e., “treatment nodes”), the extent to which there are trials comparing different pairs of these 
interventions (i.e., the adjoining lines or “edges”), and the numbers of patients associated 
with different comparisons [5].  
By studying and presenting the network geometry, we could understand how strong the 
evidence is for some treatment comparisons and whether specific comparisons are over- or 
under-represented, or even avoided (comparator preference bias) [5, 7].  
Generally, the edges between treatment nodes in the network indicate the comparisons made 
within eligible randomized trials identified during the process of study identification. The 
widths of these edges are commonly sized to proportionally reflect the numbers of studies 
evaluating each pair of treatments, and the sizes of each treatment node are typically sized to 
proportionally reflect the numbers of subjects randomized to each treatment. 
 Circles represent treatment nodes in the network; lines represent direct comparisons for 
which data are available from RCTs. Line thickness is proportionally weighted according to 
the number of studies evaluating each comparison, while nodes are proportionally weighted 
according to the number of patients that have received each treatment relative to the total 
number of participants across all studies. Examples of possible network geometries are 
presented in Fig. 3; If all of the treatments have been compared against a common 
comparator (e.g., placebo), but not among active treatment options themselves, the network 
geometry looks like a star. If all of the active treatments have been compared with each other, 
the network plot can be represented as a complex polygon with all treatment nodes connected 
to each other [Figure 3].  
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Figure 3: Examples of treatment networks.  
 
 
Note: Nodes represent a treatment or an intervention; lines show where direct comparisons exist from 1 or 
more RCTs:  
(i) “Star network”: all interventions have a single mutual comparator.  
(ii) “Single closed loop” involves 3 interventions and can provide data to calculate direct comparisons and 
indirect comparisons (mixed evidence).  
(iii) “Connected network”: all interventions have been compared with each other in several trials.  
(iv) “Complex network”: combination of start and connected networks 
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2.3 Statistical Methodology 
Network meta-analysis can be performed either with “Frequentist” or “Bayesian” 
methodologies. Both approaches were developed at the beginning of 20th century. The 
progress of Bayesian techniques was somewhat delayed because they usually require much 
more processing power than frequentist ones 
Frequentist inference has been associated with the frequentist interpretation of probability, 
specifically that any given experiment can be considered as one of an infinite sequence of 
possible repetitions of the same experiment, each capable of producing statistically 
independent results.  In this view, the frequentist inference approach to drawing conclusions 
from data is effectively to require that the correct conclusion should be drawn with a given 
(high) probability, among this notional set of repetitions. However, exactly the same 
procedures can be developed under a subtly different formulation. This is one where a pre-
experiment point of view is taken. It can be argued that the design of an experiment should 
include, before undertaking the experiment, decisions about exactly what steps will be taken 
to reach a conclusion from the data yet to be obtained. These steps can be specified by the 
scientist so that there is a high probability of reaching a correct decision where, in this case, 
the probability relates to a yet to occur set of random events and hence does not rely on the 
frequency interpretation of probability.  
Bayesian inference has often been thought of as almost equivalent to the Bayesian 
interpretation of probability and thus that the essential difference between frequentist 
inference and Bayesian inference is the same as the difference between the two 
interpretations of what a "probability" means. However, where appropriate, Bayesian 
inference (meaning in this case an application of Bayes' theorem) is used by those employing 
a frequentist interpretation of probabilities. 
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There are two major differences in the frequentist and Bayesian approaches to inference that 
is not included in the above consideration of the interpretation of probability: 
- In a frequentist approach to inference, unknown parameters are often, but not always, 
treated as having fixed but unknown values that are not capable of being treated as 
random variants in any sense, and hence there is no way that probabilities can be 
associated with them. In contrast, a Bayesian approach to inference does allow 
probabilities to be associated with unknown parameters, where these probabilities can 
sometimes have a frequency probability interpretation as well as a Bayesian one. The 
Bayesian approach allows these probabilities to have an interpretation as representing 
the scientist's belief that given values of the parameter are true. 
- While "probabilities" are involved in both approaches to inference, the probabilities 
are associated with different types of things. The result of a Bayesian approach can be 
a probability distribution for what is known about the parameters given the results of 
the experiment or study. The result of a frequentist approach is either a "true or false" 
conclusion from a significance test or a conclusion in the form that a given sample-
derived confidence interval covers the true value: either of these conclusions has a 
given probability of being correct, where this probability has either a frequency 
probability interpretation or a pre-experiment interpretation. 
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2.4 Internal and External Validity of NMA 
The external validity of the network meta-analysis will naturally be limited by the external 
validity of the RCTs included in the evidence network. Quality assessment of RCTs included 
in the analysis is crucial.  
The internal validity is based on the appropriate identification of studies that form the 
evidence network, the quality of the individual RCTs, and the extent of confounding bias due 
to similarity and consistency violations.  
Another parameter which is critical for the applicability of the outcomes in clinical practice is 
the selection of an appropriate endpoint in order to perform the comparisons among 
treatments. [Charter 4] 
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Chapter 3 – Overview of treatment options in Small Cell 
Lung Cancer 
 
3.1 Overview 
The management of SCLC is complicated by the aggressiveness of the disease. Most patients 
present with symptoms of bulky intra-thoracic disease and/or wide-spread metastases that 
cause significant debility. Due to the high prevalence of tobacco use, many patients also have 
substantial co-morbidities that contribute to their impaired performance status and limit the 
delivery of optimal treatment. These factors also make it challenging to enroll patients with 
SCLC onto appropriate clinical trials. 
Platinum-based chemotherapy is the treatment of choice in patients with both limited (LD-
SCLC) and extended (ED-SCLC) disease that has good Performance Status (PS) and organ 
function. Several prospective trials have compared platinum-based (cisplatin plus etoposide) 
versus non-platinum-based (anthracycline-based) regimens in both LD and ED patients.  
Combination chemotherapy is clearly superior to single-agent treatment in SCLC, and during 
the 1970s, the cyclophosphamide, anthracycline and vincristine (CAV) regimen became the 
standard treatment [29].  
Only in the early 1980s, the combination of cisplatin and etoposide emerged as first-line 
treatment in SCLC. Although randomized Phase III studies failed to prove a definitive 
survival benefit compared with CAV [30-32], an overview of US National Cancer Institute 
sponsored trial (conducted between 1972 and 1990) confirmed an improvement in median 
survival for patients treated with cisplatin-based regimens [33]. The EP regimen was better 
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tolerated in combination with thoracic radiotherapy and soon became the most frequently 
used chemotherapy regimen for SCLC [34].  
 
3.2 LD-SCLC  
LD-SCLC is a potentially “curable” disease in which recent progress has mainly been made 
through advances in the use of radiotherapy. Two meta-analyses have demonstrated that the 
addition of definitive thoracic radiation to chemotherapy significantly improves overall 
survival in patients with LD-SCLC [35, 36]. Further studies have shown that early thoracic 
radiotherapy resulted in a greater overall survival benefit than late radiotherapy [37].  
Although a large, randomized trial reported an added improvement in survival with hyper-
fractionated, twice daily, thoracic radio-therapy, this strategy remains controversial and 
confirmatory studies are on-going [38].  
Up to 60 % of patients with SCLC are going to develop brain metastases during the course of 
their illness. A meta-analysis of randomized trials evaluating prophylactic cranial irradiation 
(PCI) reported a significant decrease in the incidence of brain metastases and a 5.4 % 
increase in 3-year overall survival [39].  
At present, the standard-of-care for patients with LD-SCLC consists of 4-6 cycles of cisplatin 
and etoposide plus early, concurrent thoracic radiotherapy. PCI is recommended for those 
achieving a good response to initial therapy. With such treatment, objective response is noted 
in 90 % of patients with long-term survival in 25 % 
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3.3 ED-SCLC  
ED-SCLC remains an incurable disease in which the mainstay of treatment is platinum-
based, two-drug chemotherapy, such as cisplatin or carboplatin plus etoposide, with the goal 
of palliating symptoms and prolonging survival. This treatment yields an objective response 
in 60-70 % of patients with up to 10 % having a complete radiographic response. Patients 
who attain a good response are considered for PCI based on the demonstration of improved 
survival even in those with extensive-stage disease [40].  
Although chemotherapy does significantly improve quality-of-life and prolong survival for 
patients with ED-SCLC, relapse is inevitable, and only 5 % of patients remain alive 2 years 
after the initial diagnosis. Numerous chemotherapy-based strategies, including dose 
intensification, weekly administration, three- or four-drug regimens, high-dose consolidation, 
alternating or sequential non-cross-resistant regimens, and maintenance therapy, have failed 
to improve survival, and several of these approaches have resulted in excessive toxicity [41]. 
Single-agent chemotherapy is the standard treatment for patients with relapsed SCLC. While 
response rates are generally higher with combination therapy, over-all survival is not 
improved, and the toxicity of combination regimens is problematic [42].  
The benefits of subsequent therapy are strongly impacted by the duration of response to 
initial treatment, with lower response rates noted in patients who relapse within 2-3 months 
of initial therapy. Despite the relatively poor responses and short survival associated with 
second-line chemotherapy, a randomized trial comparing oral topotecan to best supportive 
care did demonstrate significantly better overall survival in patients receiving chemotherapy 
(median, 26 vs. 14 weeks; p = 0.01) [43]. 
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It is unlikely that empiric chemotherapy will lead to further significant improvements in 
outcome in patients with ED-SCLC. The overall survival of patients with ED-SCLC has 
changed little since the advent of active chemotherapy regimens in the 1970s [44]. 
Future advances will rely on efforts to better understand the underlying biology of SCLC and 
to identify molecular targets that drive survival, proliferation and metastasis. In addition, we 
must improve and broaden our clinical research infrastructure to optimize enrollment onto 
rational clinical trials. 
 
3.4 Current issues in pharmacotherapy 
3.4.1 Cisplatin versus carboplatin 
In clinical practice, EP is the most commonly used initial combination chemotherapy 
regimen; however, significant symptomatic non-hematological toxicities are related to 
cisplatin administration. Carboplatin is frequently substituted for cisplatin, but its use carries 
a greater risk of myelosuppression [45]. Although the mechanisms of action are similar, it is 
unclear whether carboplatin and cisplatin have the same clinical efficacy. 
Four RCTs have suggested similar efficacy of cisplatin and carboplatin in patients with 
SCLC, indicating carboplatin-etoposide regimen as a valid alternative in elderly or poor-risk 
patients with ED-SCLC, in consideration of the risk-benefit balance (Table 3) [49-49]. 
On these studies, a meta-analyses of individual patients data, involving 663 LD (32%) and 
ED-patients (68%), was conducted: there was no evidence of treatment difference between 
the cisplatin and carboplatin arms in terms of OS (median OS of 9.6 vs 9.4 months, 
respectively; HR 1.08, p = 0.37), progression-free survival (median PFS of 5.5 vs 5.3 months, 
respectively; HR 1.10, p = 0.25), and ORR (67.1 vs 66.0%, respectively; RR 0.98, p = 0.83) 
[50].  
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The range of toxicity of the two platinum agents was different. Carboplatin-based regimens 
were associated with a significantly higher incidence of Grade 3 hematologic toxicities 
compared with cisplatin-based. On the contrary, non-hematological side effects resulted 
higher with cisplatin-based treatment. Heterogeneity among studies was found for some 
adverse effects, probably due to the different drugs and doses used.  
Overall, the choice of the platinum compound for first-line treatment of patients with SCLC 
in clinical practice is based on the expected toxicity profile, age, the patient’s organ function 
and the patient’s comorbidities  
 
Table 3: Phase III trials comparing platinum-based regimens: carboplatin or cisplatin. 
Author and 
year 
Disease 
Stage 
Treatme
nt arms
Number 
of 
patients
Performance 
status 
ORR (%) 
PFS 
(months) 
Median 
OS 
(months)
Skarlos, 1994 
[47] 
LD/ED 
EP 71 
0-2 
LD:76; 
ED:60 
8.4 12.5 
EC 72 
LD:86; 
ED:67 
8.6 11.8 
Joss, 1995 [46] ED 
PAV 
CyMOC 
27 
0-2 
65 NA 8.6 
CV 32 29 NA 4.8 
Okamoto, 2007 
[48] 
ED 
EP 110 
0-2 
73 4.7 9.9 
EC 110 73 5.2 10.6 
Lee, 2009 [49] LD/ED 
EP 120 0-2 (ED) 63 6.3 8.1 
GC 121 2 (LD) 63 5.9 8.0 
Note: EC: Etoposide + carboplatin; EP: Etoposide + cisplatin  
 
3.4.2 First-line regimens other than platin plus etoposide 
The most recent challenge to EP has come from the combination of irinotecan plus cisplatin 
(IP). In the first Phase III trial of this regimen, Noda et al. from the Japanese Cooperative 
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Oncology Group (JCOG) randomized 154 patients with previously untreated ED-SCLC to 
either EP or IP and reported that IP resulted in significantly better response rate, progression-
free survival and overall survival (Table 4) [51].  
As expected, patients receiving IP had significantly more severe diarrhea, while those 
receiving EP had greater hematologic toxicity. However, randomized trials in Western 
patients have failed to confirm the superiority of IP over EP. Hanna et al. in North America 
and Australia compared a modified IP regimen to EP in 331 patients with previously 
untreated ED-SCLC and reported no difference in overall efficacy. As in the JCOG trial, 
there was more myelosuppression and febrile neutropenia in patients receiving EP and more 
diarrhea in those treated with IP (Table 4) [52].  
Lara et al. in the US, randomized 651 patients with previously untreated ED-SCLC to receive 
IP or EP using the same regimens and schedules as reported by Noda et al. [53]; there was no 
significant difference in response rate or survival between the two arms (Table 4). A 
European study by Zatloukal et al. randomized 405 patients with previously untreated ED-
SCLC to receive IP or EP and reported non-inferiority of IP, with response rate and TTP non-
significantly favoring EP, but overall survival non-significantly favoring IP (Table 4) [54]. 
Recently, the JCOG investigators, led by Kubota et al. reported a Phase III, randomized trial 
of IP versus EP consolidation therapy after induction with EP plus thoracic RT in patients 
with LD-SCLC [55].  
In contrast to the prior JCOG study in ED-SCLC [51], the current study failed to demonstrate 
a significant difference in PFS (1.0 vs 1.1 years, p = 0.74) or overall survival (2.8 vs 3.2 
years, p = 0.70) between IP and EP. The authors do note that the overall survival rates 
achieved in this trial are the best ever reported in LD-SCLC (5-year, EP 36 vs IP 34%), a 
finding likely due to improvements in staging and more stringent patient selection in terms of 
age and performance status. 
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The more favorable toxicity profile of carboplatin has led to the evaluation of irinotecan plus 
carboplatin (IC) in patients with SCLC. In a Phase III study, Hermes et al. randomized 209 
patients with untreated ED-SCLC to receive IC or oral etoposide plus carboplatin (EC) and 
reported a significant improvement in overall survival with IC (Table 4) [56].  
Quality-of-life measures were similar in both arms. A small, randomized Phase II study of IC 
versus EC also reported a significantly better response rate and PFS with IC, although overall 
survival was not reported (Table 4) [57]. 
Both irinotecan and topotecan are topoisomerase 1 inhibitors derived from camptothecin, 
although topotecan is generally considered to have a more favorable toxicity profile. Eckardt 
et al. randomized 784 patients with previously untreated ED-SCLC to receive either oral 
topotecan plus cisplatin (TP) or EP. Once again, efficacy was similar in both arms (Table 4) 
[58].  
As in the prior trials of IP versus EP, there was more neutropenia and febrile neutropenia in 
patients receiving EP and more diarrhea in those treated with TP. Quality-of-life analysis 
slightly favored EP (p = 0.049) [58]. ED-SCLC is a terminal disease, so many patients and 
oncologists consider quality of life to be at least as important as duration of survival. A 
similar study by Fink and collaborators, comparing TP to EP in 703 patients with untreated 
ED-SCLC, reported non-inferiority of TP, with a significant improvement in response rate 
and TTP, but only a non-significant trend in overall survival favoring TP (Table 4) [59]. 
The question of topoisomerase 1 inhibitors versus etoposide has been kept alive by meta-
analyses reporting modest improvements in overall survival with platinum plus irinotecan or 
topotecan combinations [60, 61].  
However, the poor long-term survival rates achieved with all these regimens are a clear sign 
that they are not the final answer for patients with ED-SCLC. These newer combinations (IP, 
EC and TP) do not appear to be significant steps forward and, for now, EP or EC remain the 
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standard of care for non-Japanese patients with SCLC. In Japan, IP is commonly used as a 
first-line regimen for patients with ED-SCLC. 
Encouraging data have also been reported from Phase II trials in patients with ED-SCLC with 
a variety of newer regimens, such as carboplatin plus paclitaxel and paclitaxel plus 
topotecan [62, 63].  
However, it is highly unlikely that any of these empiric regimens will result in clinically 
relevant improvements in long-term survival. Numerous chemotherapy-based strategies, 
including dose-intensification [64], dose-dense regimens [65], weekly administration [66], 
triplet therapy [67], high-dose consolidation [68], alternating or sequential non-cross-resistant 
regimens [69], maintenance therapy [70] and consolidation therapy [71], have failed to yield 
consistent or convincing improvements in survival, and several of these approaches have 
resulted in unacceptable toxicity [72]. 
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Table 4: Randomized trials of cisplatin or carboplatin plus irinotecan or topotecan in 
ED-SCLC 
Author and year 
Disease 
Stage 
Treatment 
arms 
Number of 
patients 
ORR (%) 
PFS 
(months) 
Median OS 
(months) 
Noda et al. [51] ED 
IP 77 84 4.8 12.8 
EP 77 68 6.9 9.4 
Hanna et al. [52] ED 
IP 221 48 4.1 9.3 
EP 110 44 4.6 10.2 
Lara et al. [53] ED 
IP 324 60 5.7 9.9 
EP 327 57 5.2 9.1 
Zatloukal et al. 
[54] 
ED 
IP 202 39 5.4 10.2 
EP 203 47 6.2 9.7 
Hermes et al. [56] ED 
IC 105 17  8.5 
EC 104 7  7.1 
Schmittel et al. 
[57] 
ED 
IC 35 67   
EC 35 59   
Eckardt et al. [58] ED 
TP 389 63  9.0 
EP 395 69  9.2 
Fink et al. [59] ED 
TP 358 56 6.9 11.2 
EP 345 46 6.1 10.2 
Note: EC: Etoposide + carboplatin; EP: Etoposide + cisplatin; IC: Irinotecan + carboplatin; IP: Irinotecan + 
cisplatin; TP: Topotecan + cisplatin.  
3.4.3 New medicinal products 
Recent studies have demonstrated that amrubicin, a fully synthetic anthracycline that has 
been approved for clinical use in Japan, has promising activity in patients with SCLC. As 
first-line therapy for patients with ED-SCLC, Phase II trials have reported response rates of 
79% for single-agent amrubicin and 88% for the combination of amrubicin plus cisplatin 
(AP) [73, 74].  
A recently reported Phase III study compared AP to IP in 284 previously untreated patients 
with ED-SCLC [75]. Disappointingly, the study was stopped early due to futility on interim 
analysis with similar response rates for AP and IP (78 vs 72%, p = 0.33), but with PFS (5.6 vs 
5.1 months; hazard ratio 1.42, 95% CI 1.16-1.73) and over-all survival (17.7 vs 15.0 months; 
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hazard ratio 1.43, 95% CI 1.10 -- 1.85) significantly favoring IP over AP [75].In patients with 
recurrent disease, single-agent Phase II studies of amrubicin have yielded response rates of 
21-52% [76-78]. Interestingly, response rates and survival were similar in patients with 
relapsed/sensitive and refractory/resistant disease. However, severe toxicity, mainly 
hematologic, occurred in > 90% of patients [78, 79].  
Three randomized trials have compared amrubicin to topotecan as second-line therapy in 
patients with SCLC [80-82]. 
A randomized Phase II trial from Japan compared amrubicin to topotecan in 59 patients with 
recurrent SCLC and reported significant improvements in response rate (38 vs 13%, p = 0.04) 
and disease control rate (79 vs 46%, p = 0.02) with amrubicin [80]. Response rates favoring 
amrubicin were 53 versus 21% in patients with relapsed/sensitive disease and 17 versus 0% 
in patients with refractory/resistant disease.  
Similarly, a randomized Phase II trial from the US that compared amrubicin to topotecan in 
76 patients with relapsed/sensitive SCLC demonstrated a significant improvement in 
response rate (44 vs 15%, p = 0.02) with amrubicin [81].  
Jotte et al. recently reported a Phase III trial in which 637 patients with recurrent SCLC were 
randomized in a 2:1 manner to receive either amrubicin or topotecan [82]. There was a 
significant improvement in response rate (31 vs 17%, p = 0.0002) with amrubicin, but no 
difference in median PFS (4.1 vs 4.0 months, p = 0.98) or overall survival (7.5 vs 7.8 months, 
p = 0.17). Interestingly, in the subgroup of patients with refractory/resistant disease, the 1-
year overall survival rate was significantly better with amrubicin (17 vs 8%, p = 0.019). 
While topotecan resulted in more high-grade myelosuppression, amrubicin led to a 
significantly greater rate of febrile neutropenia and infection [82]. 
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3.4.4 Targeted Therapies 
A number of molecularly targeted therapies have been evaluated in SCLC either as 
monotherapy or in combination with other anti-tumor agents. These include clinical trials in 
the first-line setting, as maintenance therapy and in relapsed SCLC. Sharp et al. recently 
published a review compiling all investigational therapies for SCLC [83]. These studies are 
reported at Tables 5 and 6 [84-121]. 
Table 5: Targeted therapies in first line treatment of small cell lung cancer 
Putative target Agent Author Phase Therapy Outcome 
Targeting angiogenesis 
VEGF-A Bevacizumab 
Pujol, 2015 [115] II/III Combination Negative 
Patton, 2006 [89] II Monotherapy 15 m OS 
Spigel 2008, [97] II Combination Stopped 
Ready, 2011 [90] II Combination 
7 m PFS, 
11.6 m OS 
Spigel, 2009 [96] II Combination 
9.1 m TTP, 
12.1m OS 
Spigel, 2011 [99] II Combination Negative 
RAF-1, VEGFR-2, 
VEGFR-3 and PDGFRb 
Sorafenib Sharma, 2014 [94] II Combination 7.4 m OS 
VEGFR-1, VEGFR-2, 
VEGFR-3, PDGFR, c-
KIT, FLT-3 and RET 
Sunitinib 
Spigel, 2012 [95] II Monotherapy 7.6 m PFS 
Ready, 2015 [91] II Monotherapy 
Improved PFS but 
not OS 
Targeting cell signaling 
BCR-Abl, c-KIT and 
PDGFR 
Imatinib 
Johnson, 2003 [85] II Monotherapy 0.8 m TTP 
Spigel, 2007 [98] II Monotherapy 
5.4 m PFS, 
8.4 m OS 
Schneider, 2010 [93] II Monotherapy 
4.3 m PFS, 
7.8 m OS 
mTOR Temsirolimus Pandya, 2007 [88] II Monotherapy 2.5 m PFS 
IGF1R Cixutumumab 
Belani, 2013 [84] II Combination Negative 
Smoothened Vismodegib 
Targeting apoptosis 
BCL-2 Oblimersen Rudin, 2008 [116] II Combination Negative 
BCL-2, MCL-1, BCL-
W, BCL-XL 
Obatoclax Langer, 2014 [117] II Combination Negative 
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Targeting DNA repair defects 
PARP 
Veliparib Owonikoko 2014 [87] I Combination Negative 
Olaparib Ongoing II Monotherapy ISRCTN73164486 
Targeting the immune system 
CTLA-4 Ipilimumab 
Reck, 2013 [118] II Combination Improved iRPFS 
Ongoing II Combination NCT01331525 
Ongoing II Combination NCT02046733 
Ongoing III Combination NCT01450761 
Note: VEGF: Vascular endothelial growth factor; VEGFR: Vascular endothelial growth factor receptor; 
PDGFR: Platelet derived growth factor receptor; c-KIT: Stem cell factor receptor; FLT3: FMS-like tyrosine 
kinase 3; RET:  Rearranged during transfection tyrosine kinase; mTOR - mammalian target of rapamycin; 
IGFR: Insulin like growth factor receptor; BCL-2: B-cell lymphoma; MCL-1:  myeloid cell leukaemia 1; 
HDAC: Histone deacetylase; PARP: Poly-ADP ribose polymerase; EGFR: epidermal growth factor receptor; 
CTLA: Cytotoxic T-lymphocyte-associated protein 4;  iRPFS: Immune-related progression-free survival. 
 
Table 6: Targeted therapies in treatment of relapsed small cell lung cancer 
Putative target Agent Author Phase Therapy Outcome 
Targeting angiogenesis 
VEGF-A Bevacizumab 
Jalal, 2010 [106] II Combination 
14.7 w PFS, 
30 w OS 
Waterhous, 2010 [114] II Combination 
17.4 w PFS, 
31.6 w OS 
Mountzios, 2012 [110] II Combination 
2.7 m PFS, 
6.3 m OS 
RAF-1, VEGFR-2, 
VEGFR-3 and PDGFRb 
Sorafenib Gitlitz, 2010 [103] II Monotherapy 
6.7 m OS, 
5.3 m OS 
VEGFR-1, VEGFR-2, 
VEGFR-3, PDGFR, c-
KIT, FLT-3 and RET 
Sunitinib Han, 2014, [104] II Monotherapy 
1.4 m PFS, 
5.6 m OS 
VEGFR-1 and VEGFR-
2 
Aflibercept Allen, 2014 [100] II Combination Negative 
VEGFR-1, VEGFR-2 
and VEGFR-3, PDGF 
and c-Kit 
Pazopanib Gandhi, 2012 [102] II Monotherapy 14.1 w PFS 
Targeting cell signaling 
EGFR Gefitinib Moore, 2006 [109] II Monotherapy 50 d TTP 
BCR-Abl, c-KIT and Imatinib Johnson, 2003 [85] II Monotherapy 1.2 m TTP 
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PDGFR Krug, 2006 [107] II Monotherapy All PD by 4 w 
mTOR Everolimus Tarhini, 2010 [112] II Monotherapy 
1.3 m PFS, 
6.7 m OS 
BCL-2, BCL-W, BCL-
XL 
Navitoclax Rudin, 2012 [111] II Monotherapy 
1.5 m PFS, 
3.2 m OS 
BCL-2, BCL-XL, BCL-
W, MCL-1 
Gossypol Heist, 2010 [105] I/II Combination 
17.4 w PFS, 
11.7 w 
Proteasome Bortezomib Lara, 2006 [108] II Monotherapy 
1 m PFS, 
3 m OS 
HDAC Panobinostat De Marinis, 2013 [101] II Monotherapy Negative 
Targeting DNA repair defects 
PARP BMN673 Wainberg, 2014 [113] I Monotherapy 18% RR 
Targeting the immune system 
PD-1/CTLA-4 
Nivolumab 
Antonia, 2016 [119] I/II Combination 
Nivolumab 18% 
ORR and 4.4 m OS, 
Combination 17% 
ORR and 8.2 m OSIpilimumab 
Antibody-drug conjugates 
CD56 
Lorvotuzumab 
mertansine 
Beck, 2012 [120] I Monotherapy 25% PR/SD 
DLL3 
Rovalpituzumab 
tesirine 
Rudin, 2015 [121] I Monotherapy 22% ORR 
Note: VEGF: Vascular endothelial growth factor; VEGFR: Vascular endothelial growth factor receptor; 
PDGFR: Platelet derived growth factor receptor; c-KIT:  Stem cell factor receptor; FLT3:  FMS-like tyrosine 
kinase 3; RET: Rearranged during transfection tyrosine kinase; mTOR - mammalian target of rapamycin; 
BCL-2: B-cell lymphoma; MCL-1: Myeloid cell leukaemia 1; HDAC: Histone deacetylase; CD5:  Neural cell 
adhesion molecule; DLL3:  delta-like 3; PARP:  Poly-ADP ribose polymerase; CTLA: Cytotoxic T-
lymphocyte-associated protein 4; EGFR:  epidermal growth factor receptor; PD-1:  programmed cell death 
protein-1. 
The majority of these trials have not found a benefit probably due to both disease and trial-
related issues. This may be reflected by the relatively small number of patients enrolled into 
clinical trials of targeted therapies in SCLC. 
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Chapter 4 – Selection of an appropriate endpoint to assess 
relative effectiveness of treatments in SCLC 
 
In oncology/hematology setting, long term outcomes are considered of high importance for 
treatment selection, both by clinicians and patients. For current standard of care, long-term 
efficacy is well characterized, at least compared to new medicinal entities, where limited data 
on long-term outcome as well as safety (including immunogenicity) are usually available at 
the time of submission. In order the outcome of a NMA to be applicable in clinical practice, it 
is of great importance to use the most appropriate endpoint, closest to clinical practice. If it 
not feasible, it is crucial to identify an alternative sensitive surrogate endpoint (Figure 4) 
 
Figure 4: Surrogate endpoints for long-term effectiveness in oncology/hematology 
 
 
The last few years have seen an increase in the number of randomized controlled trials 
(RCTs) of new agents in metastatic solid tumors using progression-free survival (PFS) as the 
primary end point. Disease progression is one of the original four categorical outcomes to 
Institutional Repository - Library & Information Centre - University of Thessaly
26/03/2018 13:04:56 EEST - 137.108.70.6
44 
describe change in tumor burden developed first by the WHO [122] and updated recently by 
the RECIST (Response Evaluation Criteria in Solid Tumors) working group. [123] In 
general, these criteria were intended for use in clinical trials that used response rate as a 
primary objective, such as phase II screening trials of new drugs. It is important to note that 
these measures were intended simply to describe what happens to tumors during therapy—
not to infer a meaningful benefit from those changes. 
However, there can be practical limitations to using OS as a primary trial end point, including 
the need for larger sample sizes and longer follow-up. An end point that is a surrogate for OS 
would be helpful in addressing these limitations but must first be validated by satisfying 
statistical criteria. [124-128] 
Foster et al [129, 130] investigated the putative surrogate endpoints of best response, 
complete response, confirmed response, and progression-free survival for associations with 
overall survival and as possible surrogate endpoints for OS, by analyzing individual 2855 
patients’ data in ten ED-SCLC first-line therapy trials. PFS demonstrated strong surrogacy 
for OS (R = 0.81) in first line ED-SCLC based on this external validation study of individual 
patient data. PFS is a good alternative end point to OS and should be considered when 
resource constraints (time or patient) might make it useful or desirable in place of OS 
Surrogacy analyses of PFS versus OS have been performed across many disease sites with 
mixed results. [131] PFS has been shown to be a valid surrogate end point for OS in 
advanced ovarian and advanced colorectal cancer.[132-135] Other disease sites, including 
advanced breast cancer,[136-139] advanced prostate cancer,[140, 141] advanced gastric 
cancer,[142] and advanced NSCLC,[143] have not supported PFS as a surrogate end point for 
OS. 
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Tumor response may be may be another surrogate for long term outcomes in ED-SCLC. 
Based on ORR and PFS reported in the ED-SCLC studies (Table 8) identified for this 
analysis [Chapter 5], the end points were well correlated.  
 
Table 7: ED-SCLC studies used to estimate correlation coefficient and equation of the 
regression line 
Treatment Study X Y X⋅Y X⋅X Y⋅Y 
Cisplatin + Etoposide versus 
Cisplatin + Irinotecan 
Noda 2002 [51] 0.38 0.43 0.1634 0.1444 0.1849 
Hanna 2006 [52] 0.83 0.99 0.8217 0.6889 0.9801 
Lara 2009 [53] 0.89 0.74 0.6586 0.7921 0.5476 
Zatloukal 2010 [54] 1.34 0.88 1.1792 1.7956 0.7744 
Cisplatin + Etoposide versus 
Carboplatin + Etoposide 
Okamoto 2007 [48] 1.03 0.77 0.7931 1.0609 0.5929 
Cisplatin + Etoposide versus 
Cisplatin + Topotecan 
Eckardt 2006 [58] 1.30 1.00 1.3 1.69 1 
Fink 2012 [59] 0.67 0.84 0.5628 0.4489 0.7056 
Carboplatin + Etoposide 
versus 
Carboplatin + Irinotecan 
Schmittel 2011 [144] 0.92 0.74 0.6808 0.8464 0.5476 
Carboplatin + Etoposide 
versus 
Cisplatin + Irinotecan 
Socinski 2009 [145] 2.36 1.37 3.2332 5.5696 1.8769 
Cisplatin + Irinotecan versus 
Cisplatin + Pemetrexed 
Socinski 2006 [147] 1.21 1.35 1.6335 1.4641 1.8225 
X: Odd Ration for Objective Response Rate, Y: Hazard Ration for Overall Survival 1Y post treatment 
 
Specifically a  using a weighted regression model with and without taking into account 
measurement error in the independent variable, revealed a strong uphill linear relationship 
(r=0.7811) 
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The estimated regression line of the adjusted model was Y = 0.454 + 0.419 x, which predicts 
an approximately 40% increase in log HR of PFS for every unit increase in the log OR of 
ORR. (Figure 5) 
Figure 5: Equation of the regression line 
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Chapter 5 – Assessing the relative effectiveness of 
treatments in SCLC - Frequentist Approach 
Bakalos G et al. Assessing the relative effectiveness and tolerability of treatments in small 
cell lung cancer: a network meta-analysis. Cancer Epidemiol. 2013 Oct;37(5):675-82 
 
5.1 Introduction 
In order to evaluate the relative merits of the different treatments for SCLC based on the 
mode of action of each chemotherapy agent (or combination of individual chemotherapy 
agents), we systematically searched and catalogued all available published RCTs in SCLC. 
Then, we performed a network of multiple treatments analysis (network meta-analysis), 
involving direct analysis (synthesis of RCTs with the same treatment comparisons) and 
indirect analysis (comparison between treatments using an intermediate comparator). In the 
absence of direct comparison between treatments, the effect size can only be estimated only 
using an indirect comparison approach. 
 
5.2 Materials & Methods 
5.2.1 Search strategy-Selection of RCTs 
We searched PubMed, EMBASE, and the Central Registry of Controlled Trials of the 
Cochrane Library to identify all RCTs that investigated chemotherapy regimens in adult 
patients with histologically proven SCLC. The search was limited to English language, 
RCTs, adults, and concerned the time period from 1980 until May 1st, 2011. The articles were 
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identified using as search criterion the terms: “small cell lung cancer” and “chemotherapy”. 
The reference lists of the retrieved articles were also reviewed to identify additional 
publications. The search strategy for the selection of the eligible RCTs is shown in Figure 6.  
 
Figure 6: Flow diagram of the screening process and RCTs selection for multiple-
treatments meta-analysis of treatments for SCLC 
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5.2.2 Eligibility criteria  
RCTs that compared at least two arms of different chemotherapy regimens in chemotherapy 
naïve patients with histologically proven SCLC were included in the network analysis. Only 
studies that provided sufficient data to calculate odds ratios (ORs) for estimating the 
magnitude of difference between treatments, and the corresponding precision were 
considered.  
The following studies were excluded: 
- Studies comparing second line chemotherapy treatments, 
-  Studies reporting radiotherapy interventions, i.e. radical radiotherapy in combination 
with chemotherapy or chemotherapy administration for sensitization to radiation, 
-  Studies reporting surgical interventions,  
-  Studies reporting adjuvant chemotherapy (i.e. chemotherapy following radical surgical 
intervention) or neo-adjuvant chemotherapy (i.e. chemotherapy prior to radical surgical 
interventions), 
- Studies reporting supportive care interventions or comparison of chemotherapy with 
chemotherapy plus conventional supportive care and  
- Follow-up and extension studies. In addition, studies with a crossover design, meeting 
abstracts and conference proceedings were excluded.  
In RCTs involving more than two treatment arms, each pair-wise treatment comparison was 
considered as different study. Also, RCTs providing data for different SCLC stages were 
considered as separate studies in the analysis. In order to avoid the inclusion of duplicated 
data, the retrieved studies were appraised by geographic location, author names and period of 
study. Then, in studies with overlapping patients, the largest one was included in the analysis. 
Only studies conducted after approval from national ethical committees were considered. 
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5.2.3 Data extraction and outcomes definition 
The following information was extracted from each eligible article: name of first author, year 
of publication, country of origin, reported stage of SCLC, sample size (randomized patients, 
totally and per arm), types and intensity (dose and duration) of chemotherapies, effect size of 
each outcome of interest and chemotherapy regimen. Data extraction was undertaken by 2 
investigators, independently. The overall agreement rate was 89%. Any disagreement was 
resolved by a third independent investigator. 
Two primary outcomes were considered to assess relative effectiveness (CR and ORR). 
Complete Response (CR) is achieved when all tumor lesions are disappeared after treatment 
initiation. Objective Response Rate (ORR) is the portion of patients with a predefined amount 
of tumor size reduction; ORR is defined as the sum of CR and partial response and it is a 
direct measure of drug antitumor activity. However, this exercise was based only on ORR 
(CR based analyses are presented as supplementary materials) 
Among the many adverse events after treatment with chemotherapy, we chose to record the 
neutropenia (NP) and febrile neutropenia (FNP) because they are considered the most 
important ones.  
 
5.2.4 Treatment definition 
Chemotherapy regimens containing the same chemotherapy agents, irrespective of dosage 
scheme and maximum duration of each chemotherapy cycle, were defined as the same 
treatment since we are interested in the assessment of the relative effectiveness of the 
different agent-based therapies. In addition, the effect of different dosage schemes and 
chemotherapy cycle intensity remains unresolved [147].  
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Furthermore, the current grouping allows the definition of a less complicated and analysable 
network. The combination of cisplatin and etoposide (EP) was set as the reference treatment 
in the subsequent treatment comparisons since it is the standard first line treatment and the 
most commonly investigated chemotherapy regimen.  
5.2.5 Statistical methods – Frequentist Analysis 
Treatments were compared using odds ratios (ORs) with their respective 95% confidence 
intervals (CI). When more than two studies compared the same treatments, random effects 
(RE) pooled OR was calculated [148]. The RE model incorporates the between study 
variability and it is more conservative than the fixed effects model [149].  
Indirect comparison was performed for treatments not compared directly [10]. Then, in 
comparing two treatments, A and B, where each treatment was compared directly with 
treatment C, the OR for comparing A and B was calculated using the following principle: 
ln(ORAvsB)=ln(ORAvsC)-ln(ORBvsC), and the respective 95% (CI) was estimated 
assuming asymptotic normality and lack of covariance [3, 10, 13, 150, 151] (Figure 1). 
The network of treatments was constructed based on all investigated comparisons between 
treatments and the indirect analysis was performed utilizing all the possible pathways 
provided by the network. The OR was considered significant when the 95% CI included the 
one (“1”).  
The network graph was built using yFiles.NET (yWorks GmbH, Tübingen, Germany, 
http://www.yWorks.com) [152] and the network analysis was carried out using NET-MS 
(http://netms.med.uth.gr). MetaAnalyst (Evidence-Based Practice Center, Tufts Medical 
Center, Boston, MA, USA, http://tuftscaes.org/meta_analyst) [153] was used to validate the 
findings of data syntheses.  
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5.3 Results 
5.3.1 Eligible studies and summary characteristics 
The literature search in PubMed, EMBASE and Cochrane Central Register of Controlled 
Trials identified 243 articles that met the search criterion. After title selection and abstract 
reviewing of the articles, 98 articles from all databases were judged to be potentially relevant 
and they were reviewed in their entirely. Finally, 71 articles were selected for inclusion the 
network analysis: 71 articles for the outcome CR, 69 for ORR, 23 for NP and 5 for FNP. The 
articles were published between 1980 and 2011. The summary characteristics of included 
RCTs in the multiple treatments meta-analysis is shown in Table 9.  
Table 8: Characteristics of 71 included randomized controlled trials (RCTs) in the 
network of treatments meta-analysis 
Characteristic Number 
Number of Interventions 91 
Number of Studies 71 
Total Number of Patients in Network 16026 
Number of Two-arm Studies 63 
Number of Multi-Arms Studies 8 
 
The characteristics of the individual RCTs including efficacy/tolerability results and their 
quality assessment are shown in Supplementary Tables 2-4 and the definition of the 
treatments is given in Supplementary Table 5.  
In total, the eligible studies involved 16,026 randomly assigned patients with SCLC and the 
majority of them were male (72%) while the median age was 61 (55-74) years. Most of the 
articles involved studies carried out in the US (21.1%) and 18.3% of them were multicenter 
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trials, involving several countries. 83.7% (63/71) of the studies included two comparing 
treatment arms and only 11.3% of them compared more than two arms.  
More than half of the studies (37/71) included patients with extended disease, while two 
studies included patients with limited disease and 32 patients with ED and LD. The median 
sample size was 230 (12-455) patients.  
Overall survival was reported in 67 articles. Overall, the median ORR was 65.2% (10.0%-
96.9%) while the median overall survival was 10.3 (1.0-27.7) months. Adverse events of 
grade 3-4 were reported for 58.5% (9,371) of the patients. Almost half patients experienced 
grade 3-4 neutropenia (53.1%) and leucopenia (44.3%). Thrombocytopenia and anemia was 
reported in 22.0% and 19.8% of the patients, respectively. 
In assessing the quality of reporting, seven items were considered:  
- Precise details of the interventions in each arm,  
- Description of study end-points,  
- Description of sample size estimation,  
- Method of randomization (sequence generation),  
- Implementation of randomization,  
- Blinding, and  
- Participant flow.  
The majority of studies were open-label and only two studies were blinded. The precise 
details of the interventions in each arm were reported in all studies, while the study end-
points and the sample size estimation were reported in 50 (70.4%) and 54 (76%) studies 
respectively. Despite the fact that the method of randomization was described in 32 (45%) 
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reports, only two reports provided information about the implementation of randomization 
(2.8%). The participant flowchart was described in 66 studies (93%).  
5.3.2 The networks 
The geometry of the network of comparisons for ORR is depicted in Figure 7; the other 
outcomes are represented in Supplementary Figures 1 - 3.  
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Figure 7: Network of direct comparisons for the outcome “Objective Response Rate”.  
 
In the network figure, the size of the circles was directly related to the number of RCTs 
investigated each treatment, while the thickness of connecting lines was directly related to the 
number of available direct comparisons. More specifically, common treatments [e.g. EP] that 
were compared by more RCTs were drawn with larger circles whereas infrequently 
investigated regimens (eg. Cisplatin plus Doxorubicin) were represented by smaller circles. 
However, most of the treatments were compared against EP, which represented the most 
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commonly used treatment in the RCTs (26 direct comparisons). Carboplatin plus Etoposide 
involved the biggest sample size of randomized patients (455 patients). All regimens are 
listed in Supplementary Table 5. 
5.3.3 Direct analysis for comparing treatments with EP 
Sixteen treatments were compared directly with EP in 18 trials [32, 48, 49, 51, 54, 58, 67, 
154, 155, 156, 157, 158, 159, 160, 161, 162, 163, and 164]:  
• Cyclophosphamide plus Doxorubicin (CAV),  
• Cisplatin plus Etoposide plus Ifosfamide (VIP),  
• Cyclophosphamide plus Doxorubicin plus Etoposide plus GCSF [ACE (intensified)],  
• Cisplatin plus Epirubicin (PEP),  
• Cisplatin plus Topotecan (TC),  
• Cisplatin plus Etoposide/Cyclophosphamide plus Doxorubicin plus Vincristine 
(CAV/EP),  
• Cisplatin plus Etoposide plus GCSF [EP (intensified)],  
• Carboplatin plus Etoposide (EC),  
• Carboplatin plus Gemcitabin (GEMCAR),  
• Cisplatin plus Irinotecan (IP),  
• Cisplatin plus Cyclophosphamide plus Etoposide plus Epirubicin (CCEE),  
• Cisplatin plus Etoposide plus Megestrol acetate (EP+Ma),  
• Cisplatin plus Etoposide plus interferon alpha (EP + IFNA-a),  
• Etoposide plus Ifosfamide (IE) and  
• Cisplatin plus Etoposide plus Paclitaxel (PET).  
The numbers of direct comparisons with EP for the outcomes CR, ORR, NP and FNP were 
18, 17, 9 and 1, respectively. None of the treatments showed better response compared to EP 
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for both efficacy outcomes. The significant results derived from the direct analysis are shown 
in Table 9; the treatments are sorted according to their effect sizes. The results of all direct 
comparisons are shown in Supplementary Table 6.  
Table 9: Direct analysis results for comparing treatments for small cell lung cancer 
(SCLC) with reference treatment (Cisplatin + Etoposide, EP) by outcome. The 
treatments were sorted according to their significance and magnitude of effect size 
Treatment Stage 
Patients, 
No OR (95% CI) P-value 
Patients with objective response 
Cisplatin + Cyclophosphamide + Etoposide 
+ Epirubicin 
ED 226 2.07 (1.17- 3.67) 0.01 
Cisplatin + Etoposide + Megestrol acetate LD, ED 243 0.55 (0.31-0.99) 0.05 
Patients with neutropenia 
Cyclophosphamide + Doxorubicin + 
Etoposide + GCSF ED 280 7.37 (3.72-14.56) <0.01 
Cisplatin + Cyclophosphamide + Etoposide 
+ Epirubicin 
ED 226 5.59 (1.83-17.1) <0.01 
Cisplatin + Epirubicin  LD, ED  402 0.54 (0.37-0.81) <0.01 
Cisplatin + Topotecan  LD, ED 784 0.27 (0.2-0.39) <0.01 
 
Patients with complete response: No regimen was significantly different than EP (P≥0.05).  
Patients with objective response: The treatment combination Cisplatin plus 
Cyclophosphamide plus Etoposide plus Epirubicin (CCEE) produced better response 
[OR=2.07 (1.17-3.67)], whereas Cisplatin plus Etoposide plus Megestrol acetate (EP+Ma) 
derived worse response [OR=0.55 (0.31-0.99)].  
Tolerability: Two treatment combinations produced worse tolerability (in terms of NP) than 
EP (Cyclophosphamide plus Doxorubicin plus Etoposide plus GCSF and Cisplatin plus 
Cyclophosphamide plus Etoposide plus Epirubicin) and two treatments shown better 
tolerability (P<0.01) (Table 9).  
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Regarding FNP, only one treatment (Cisplatin plus Etoposide plus Ifosfamide) was compared 
directly to EP, producing non-significant result [OR=1.81 (0.97, 3.40)] [158].  
Indirect analysis for comparing treatments with EP 
Table 10 shows the indirect analysis significant results (P<0.05); the treatments are sorted 
according to their effect size. None of the treatments derived a better response than EP for 
both efficacy outcomes.  
Table 10: Indirect analysis results for comparing treatments for small cell lung cancer 
(SCLC) with reference treatment (Cisplatin + Etoposide) by outcome, for treatments 
that produced significantly (P<0.05) different response that reference treatment 
Treatment OR (95% CI) p value 
Patients with complete response 
Etoposide 0.36 (0.14-0.88) 0.03 
Carboplatin + Ifosfamide 0.31 (0.11-0.88) 0.03 
Etoposide (intensified) 0.13 (0.02-0.65) 0.01 
Patients with objective response 
Cisplatin + Doxorubicin + Etoposide + Vincristine 
(intesified) 
3.79 (1.77-8.12) <0.01 
Ifosfamide + Mesna 0.43 (0.26-0.70) <0.01 
Carboplatin + Pemetrexeb 0.41 (0.21-0.79) <0.01 
Etoposide 0.40 (0.24-0.68) <0.01 
Doxorubicin + Etoposide + Vincristine 0.40 (0.17-0.94) 0.04 
Cyclophosphamide + Doxorubicin + Etoposide 0.38 (0.16-0.93) 0.03 
Teniposide 0.35 (0.21-0.57) <0.01 
Cisplatin 0.33 (0.18-0.61) <0.01 
Carboplatin  + Ifosfamide  0.25 (0.066-0.94) 0.04 
Etoposide (intensified) 0.006 (0.00-0.46) 0.02 
Patients with neutropenia 
Carboplatin + Pemetrexeb 0.26 (0.09-0.76) 0.01 
 
However, one treatment [Cisplatin plus Doxorubicin plus Etoposide plus Vincristine 
(intensified)] showed better response for the outcome ORR but, this treatment showed worse 
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tolerability in the direct analysis. The results of all indirect comparisons are shown in 
Supplementary Table 6.  
Patients with complete response: None treatment showed better outcome than EP (P≥0.05). 
However, the analysis indicated that monotherapy with etoposide (either standard or 
intensified) and combination therapy with Carboplatin plus Ifosfamide have less comparative 
effectiveness [OR= 0.36 (0.14-0.88), OR=0.13 (0.02-0.65) and OR=0.31 (0.11-0.88), 
respectively]. 
Patients with objective response: Only one treatment combination yielded better response 
to Cisplatin plus Etoposide: Cisplatin plus Doxorubicin plus Etoposide plus Vincristine 
(intesified) [OR=3.79 (1.77-8.12)]. However, nine treatments (table 10) revealed worse 
response: 
• Ifosfamide plus Mesna, 
• Carboplatin plus Pemetrexeb,  
• Etoposide,  
• Doxorubicin plus Etoposide plus Vincristine,  
• Cyclophosphamide plus Doxorubicin plus Etoposide,  
• Teniposide,  
• Cisplatin,  
• Carboplatin plus Ifosfamide and viii) Etoposide (intensified)  
Tolerability: Only the treatment Carboplatin plus Pemetrexeb indicated a better tolerability 
for the outcome NP [OR=0.26 (0.09-0.76)]. For the outcome FNP, there is only one study 
[154] reporting this outcome (see direct analysis section) and thus, the comparative 
tolerability of treatments was not evaluated further.  
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5.3.4 Sub-analysis of most common interventions in SCLC 
A sub-analysis performed including only the most commonly used interventions in ED-
SCLC. Specifically we have isolated studies reflecting to current standard of care (48, 51, 54, 
56, 59, and 157) reporting outcomes from various comparisons of the following 
interventions: Cisplatin+Etoposide, Carboplatin+Etoposide, Cisplatin+Irinotecan, and 
Cisplatin+Topotecan. The sub-network is reflected at figure 8 
Figure 8: Network Diagram of most common interventions 
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Six studies included, where 1151 out of 1864 achieved objective response rate following 
chemotherapy treatment. The network characteristics, the intervention characteristics as well 
as the direct comparison characteristics are summarized at tables 11, 12 and 13, respectively. 
Table 11: Network Characteristics 
Characteristic Number 
Number of Interventions 6 
Number of Studies 6 
Total Number of Patients in Network 1'864 
Total Number of Events in Network 1'151 
Total Possible Pairwise Comparisons 15 
Total Number Pairwise Comparisons With Direct Data 5 
Number of Two-arm Studies 6 
Number of Multi-Arms Studies 0 
Number of Studies With  No Zero Events 6 
Number of Studies With At Least One Zero Event 0 
Number of Studies with All Zero Events 1 
 
Table 12: Intervention Characteristics  
Treatment   
# 
Studies  
# 
Events 
# 
Patients
Aggregate 
Rate 
Min. 
Rate 
Max. 
Rate 
Cisplatin+Etoposide  5 562 900 0.6244 0.4631 0.7273 
Cisplatin+Topotecan  1 245 389 0.6298 0.6298 0.6298 
Cisplatin+Etoposide+GCSF  1 65 109 0.5963 0.5963 0.5963 
Cisplatin+Irinotecan  2 144 279 0.5161 0.3911 0.8442 
Carboplatin+Etoposide 2 103 147 0.7007 0.6216 0.7273 
Carboplatin+Etoposide+GCSF 1 32 40 0.8000 0.8000 0.8000 
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Table 13: Direct Comparison Characteristics 
Comparison # Studies 
# 
Patients 
# Events 
Cisplatin+Etoposide  vs. Cisplatin+Topotecan 1 784 517 
Cisplatin+Etoposide  vs. Cisplatin+Etoposide+GCSF 1 224 129 
Cisplatin+Etoposide  vs. Cisplatin+Irinotecan 2 559 290 
Cisplatin+Etoposide  vs. Carboplatin+Etoposide 1 220 160 
Carboplatin+Etoposide vs. Carboplatin+Etoposide+GCSF 1 77 55 
 
As it was expected from previous analyses, none of the treatments was significantly different 
compared to cisplatin plus etoposide, in terms of achieving ORR. 
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Chapter 6 – Assessing the relative effectiveness of 
treatments in SCLC - Bayesian Approach 
 
6.1 Introduction 
Additional analyses were performed by applying this time Bayesian statistics. For the 
purposes of this analysis we used WinBUGS (the MS Windows operating system version of 
BUGS: Bayesian Analysis Using Gibbs Sampling), which is a versatile package that has been 
designed to carry out Markov chain Monte Carlo (MCMC) computations for a wide variety 
of Bayesian models [165]. The software is currently distributed electronically from the 
BUGS Project website (http://www.mrc-bsu.cam.ac.uk/bugs/overview/contents.shtml).  
We used a freely available Microsoft-Excel-based tool called NetMetaXL, programmed in 
Visual Basic for Applications, which provides an interface for conducting a Bayesian 
network meta-analysis using WinBUGS from within Microsoft Excel [166]. This tool allows 
the user to easily prepare and enter data, set model assumptions, and run the network meta-
analysis, with results being automatically displayed in an Excel spreadsheet. It also contains 
macros that use NetMetaXL’s interface to generate evidence network diagrams, forest plots, 
league tables of pairwise comparisons, probability plots (rankograms), and inconsistency 
plots within Microsoft Excel. This tool was developed to simplify running and reporting 
network meta-analyses and to highlight how NetMetaXL can be used to facilitate consistent 
reporting and more efficient and transparent critical appraisal of network meta-analyses 
submitted to HTA organizations such as the Canadian Agency for Drugs and Technologies in 
Health (CADTH) and the National Institute for Health and Care Excellence (NICE), as well 
as to journals which publish network meta-analyses. 
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6.2 Results 
6.2.1 Sub analysis of most common interventions in SCLC 
As it was presented at 5.3.4, a sub-analysis performed on a subnetwork of the most common 
interventions in SCLC. The network diagram (figure 8), network characteristics (table 11), 
intervention characteristics (table 12), and direct comparison characteristics (table 13) were 
presented in Capter 5.  
New analyses with Bayesian statistics reveals that carboplatin+etoposide combined with 
GCSF had the bigger treatment effect size (Figure 9) 
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Figure 9: Forrest Plot of most common interventions in SCLC  
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The summary league table is shown in tables 14 (Fixed Effects) and 15 (Random Effects). 
The league table arranges the presentation of summary estimates by ranking the treatments in 
order of most pronounced impact on the outcome under consideration, based on SUCRA 
[165]. SUCRA (table 16), the surface under the cumulative ranking, is a simple numerical 
summary of the probabilities. It is 100% when a treatment is certain to be the best and 0% 
when a treatment is certain to be the worst. SUCRA values enable the ranking of treatments 
overall for a particular outcome. In this particular analysis Carboplatin+Etoposide +GCSF is 
listed in the top left of the diagonal of the league table because it was associated with the 
most favorable SUCRA for ORR, while Cisplatin+Topotecan  is listed in the bottom right of 
the diagonal of the league table because it was associated with the least favorable results. For 
interpretation purposes, the results are read from top to bottom and left to right.  
Probability bars (or rankograms) were developed within NetMetaXL, to visualize the 
probability that each treatment is ranked first, second, and so on for a particular outcome. 
These rankograms are depicted as stacked vertical bar charts for all treatments (figure 10). 
 
Table 14: Rankogram of most common interventions in SCLC, FE 
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Table 15: Rankogram of most common interventions in SCLC, RE 
 
Figure 10: Stacked Bar Chart of most common interventions in SCLC 
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Table 16: SUCRA of most common interventions in SCLC 
Treatment SUCRA 
Carboplatin+Etoposide+GCSF 0.8911 
Cisplatin+Etoposide+GCSF  0.5847 
Cisplatin+Irinotecan  0.5114 
Cisplatin+Etoposide  0.4331 
Carboplatin+Etoposide 0.4146 
Cisplatin+Topotecan  0.1651 
 
Assessment of inconsistency is crucial in the conduct of any network meta-analysis. 
Inconsistency can be thought of as a conflict between ‘direct’ and ‘indirect’ evidence [27]. 
Similar to heterogeneity, inconsistency is caused by imbalances in effect modifiers from 
study to study, specifically by an imbalance in the distribution of effect modifiers in the direct 
and indirect evidence [27]. NetMetaXL allows users to assess inconsistency by comparing 
the deviance residuals and DIC statistics in fitted consistency and inconsistency models. The 
methods employed are described at NICE Technical Support Documents (TSD) series. 
Inconsistency for this analysis was very limited, both in fixed and random effects (Figure 11). 
Figure 11: Inconsistency results of most common interventions in SCLC 
 
As a conclusion from this analysis, we confirmed that cisplatin+ etoposide is equal to 
carboplatin+etoposide. However, if we co-administrate GCSF with carboplatin+etoposide in 
order to minimize the well known risk of myelosuppression associated to carboplatin [45], it 
is revealed to be the best treatment option.  
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6.2.2 Platin-pooled data sub-analysis in ED-SCLC 
Additional analysis performed only for patients with ED SCLC. All studies reporting 
interventions either in patients with LD-SCLC or they reported mixed LD/ED SCLC results, 
were excluded (Abratt RP, 1991, Altinbas M, 2004, Ardizzoni A, 2002, Artal-Cortes A, 
2004, Baka S, 2008, Baka S, 2010, Bork E, 1991, Chahinian AP, 1989, Ettinger DS, 1990, 
Ettinger DS, 2002, Fukuoka M, 1997, Girling DJ, 1996, Grote T, 2005, Heigener DF, 2009, 
Hirsch FR, 1987, Hirsch FR, 2001, James LE, 1996, Joss RA, 1995, Joss RA, 1995(2), 
Lassen U, 1996, Lee SM, 2009, Leyvraz S, 2008, Lorigan P. 2005, Miller AA, 1995, Milroy 
R, 1993, Miyomoto H, 1992, Murray N, 1999, Nagel S, 2011, Postmus PE, 1992, Postmus 
PE, 1996, Rowland KM, 1996, Schmittel A, 2006, Sculier JP, 1990, Sculier JP, 1993, Sculier 
JP, 2001, Seifart U, 2005, Seifart U, 2007, Sekine I, 2003, Slevin ML, 1989, Souhami RL, 
1994, Souhami RL, 1997, Steward WP, 1998, Urban T, 1999, White SC, 2001, Woll PJ, 
2001). 
As a result several studies were disconnected from the network and were excluded as well 
(De Marinis F, 2005, Kanitz E, 1992, Monnet I, 1992, Reck M, 2003).  
Additional literature analysis was perfomed up to June 30th, 2016 and 14 new trials were 
identified (Supplementary table 8) 
Based on previously reported outcomes [Charter 5], cisplatin and carboplatin arms were 
pooled together. 
The network diagram is presented at figure 12. 
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Figure 12: Network diagram of platin-pooled data sub-analysis in ED-SCLC 
 
The network includes 12 studies exploring 5 interventions. 3'961 pts were enrolled; of those, 
2'315 achieved objective response rate. The network characteristics, intervention 
characteristics and direct comparison characteristics are presented at tables 17, 18 and 19, 
respectively. 
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Table 17: Network characteristics of platin-pooled data sub-analysis in ED-SCLC 
Characteristic Number 
Number of Interventions 5 
Number of Studies 12 
Total Number of Patients in Network 3'961 
Total Number of Events in Network 2'315 
Total Possible Pairwise Comparisons 10 
Total Number Pairwise Comparisons With Direct 
Data 5 
Number of Two-arm Studies 12 
Number of Multi-Arms Studies 0 
Number of Studies With  No Zero Events 12 
Number of Studies With At Least One Zero Event 0 
Number of Studies with All Zero Events 0 
 
Table 18: Intervention characteristics of platin-pooled data sub-analysis in ED-SCLC 
Treatment   # Studies  
# 
Events 
# 
Patients
Aggregate 
Rate 
Min. 
Rate 
Max. 
Rate 
Platin+Etoposide 10 991 1764 0.5618 0.4340 0.7000 
Platin + Irinotecan 7 626 1'097 0.5706 0.3911 0.8442 
Platin + Paclitaxel 1 23 34 0.6765 0.6765 0.6765 
Platin + Topotecan 3 442 747 0.5917 0.4167 0.6298 
Platin + 
Ambrubicin 3 233 319 0.7304 0.6667 0.7786 
 
Table 19: Direct Comparison Characteristics of platin-pooled data sub-analysis in ED-
SCLC 
Comparison # Studies 
# 
Patients
# 
Events 
Platin+Etoposide vs. Platin + 
Irinotecan 6 1'810 984 
Platin+Etoposide vs. Platin + 
Topotecan 2 1'464 861 
Platin + Paclitaxel vs. Platin + 
Topotecan 1 46 28 
Platin+Etoposide vs. Platin + 
Ambrubicin 2 359 231 
Platin + Irinotecan vs. Platin + 
Ambrubicin 1 282 211 
 
 
 
Institutional Repository - Library & Information Centre - University of Thessaly
26/03/2018 13:04:56 EEST - 137.108.70.6
73 
The combinations of platin with paclitaxel, platin with irinotecan and platin with topotecan 
were not significantly superior to platin plus etoposide. Only platin plus ambrubicin was 
marginally significantly better. (Figure 13) 
Figure 13: Forest plot of platin-pooled data sub-analysis in ED-SCLC 
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SUCRA values supporting that combination of platin plus paclitaxel provides the best 
probability for ORR in ED-SCLC (SUCRA 91%), followed by platin plus ambrubicin (73%), 
while the combination of platin plus etoposide provides the lowest probability of success 
(SUCRA 15%) (Tables 20-22, Figure 14) 
Table 20: League table of platin-pooled data sub-analysis in ED-SCLC - FE 
Platin + 
Paclitaxel         
2.12 
(0.51 – 9.51) 
Platin + 
Ambrubicin       
2.97 
(0.74 – 12.69) 
1.40 
(0.98 – 2.01) 
Platin + 
Irinotecan     
3.05 
(0.78 – 12.66) 
1.44 
(0.96 – 2.16) 
1.03 
(0.78 – 1.36) 
Platin + 
Topotecan   
3.25 
(0.81 – 13.77) 
1.53 
(1.08 – 2.17) 
1.09 
(0.91 – 1.31) 
1.07 
(0.86 – 1.32) Platin+Etoposide 
 
Table 21: League table of platin-pooled data sub-analysis in ED-SCLC - RE 
Platin + 
Paclitaxel         
2.26 
(0.36 – 14.09) 
Platin + 
Ambrubicin       
2.88 
(0.49 – 16.19) 
1.30 
(0.65 – 2.39) 
Platin + 
Irinotecan     
3.11 
(0.61 – 15.62) 
1.40 
(0.57 – 3.27) 
1.07 
(0.53 – 2.32) 
Platin + 
Topotecan   
3.34 
(0.59 – 18.27) 
1.49 
(0.78 – 2.72) 
1.15 
(0.80 – 1.74) 
1.07 
(0.57 – 2.00) Platin+Etoposide 
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Figure 14: Rankogram of platin-pooled data sub-analysis in ED-SCLC 
 
 
Table 22: SUCRA of platin-pooled data sub-analysis in ED-SCLC 
Treatment SUCRA 
Platin + Paclitaxel 0.9093 
Platin + Ambrubicin 0.7277 
Platin + Irinotecan 0.3986 
Platin + Topotecan 0.3093 
Platin+Etoposide 0.1552 
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Inconsistency for this analysis was very limited, both in fixed and random effects (Figure 15). 
Figure 15: Inconsistency results of platin-pooled data sub-analysis in ED-SCLC 
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6.2.3 Sub-analysis – New treatments 
An additional analysis was performed in order to estimate the impact of investigational 
treatments. 11 interventions, including current standard of care were compared in 17 studies 
which enrolled 4'605 patients. The network characteristics and are presented at table 23. 
Table 23: Network characteristics of platin-pooled data sub-analysiscompared to 
investigational treatments in ED-SCLC 
Characteristic Number 
Number of Interventions 11 
Number of Studies 17 
Total Number of Patients in Network 4'605 
Total Number of Events in Network 2'649 
Total Possible Pairwise Comparisons 55 
Total Number Pairwise Comparisons With Direct 
Data 12 
Number of Two-arm Studies 16 
Number of Multi-Arms Studies 1 
Number of Studies With  No Zero Events 17 
Number of Studies With At Least One Zero Event 0 
Number of Studies with All Zero Events 0 
 
Based on the SUCRA analyses (table 24, figure 16), new treatments are anticipated to 
improve ORR in ED-SCLC. However, are not significantly differentiated from current 
standard of care and further investigation is needed to drive conclusions on how these 
treatments would be better utilized in clinical practice.  
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Table 24: SUCRA of platin-pooled data sub-analysiscompared to investigational 
treatments in ED-SCLC 
Treatment SUCRA 
Platin + Paclitaxel + Ipilimumab  0.945 
Platin+Etoposide 0.7389 
Platin + Topotecan 0.6446 
Platin + Etoposide + Cixutumumab 0.6014 
Platin + Irinotecan 0.5939 
Platin + Etoposide + Vismodegib 0.4404 
Platin + Etoposide + Bevacizumab 0.3897 
Platin + Etoposide + aBcl2 0.3845 
Platin + Ambrubicin 0.3368 
Platin + Belotecan 0.2993 
Platin + Paclitaxel 0.1253 
 
Figure 16: Rankogram of platin-pooled data sub-analysiscompared to investigational 
treatments in ED-SCLC 
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Charter 7 – Discussion 
Herein, we have presented a comprehensive and systematic assessment of the current status 
of treating SCLC.  
The primary aim of the present study was to explore methodological aspects related to 
network meta-analysis, especially in oncology field. For the purposes of this analysis, SCLC 
was used as an example provide an assessment of the relative effectiveness of treatments in 
SCLC, especially in the absence of head-to-head comparisons, and to direct future research in 
SCLC treatment.  
We carried out a network analysis of all published RCTs in SCLC, using both “Frequentist” 
and “Bayesian” methodologies.  
 The frequentist network analysis involved the following steps: direct comparison of 
treatments, indirect comparison and combination of direct and indirect comparison. The 
secondary aim was to reveal the necessity to performing large RCTs for head-to-head 
comparisons of treatments. There are no studies involved more than 500 patients and the 
various chemotherapy combinations have not compared to a standard treatment such as EP. 
The network consisted of 91 treatments, involving 18 direct comparisons for the outcome 
CR, 17 for the outcome ORR and 10 for the tolerability.  
The analysis of the network indicated that only two regimens might have comparable 
effectiveness to EP: The application of network analysis of treatments makes optimal use of 
all available published data and provides insight in the relative effectiveness of different 
treatments (monotherapies and combination therapies) [167].  
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However, the selection of the optimal treatment is a difficult task and network analysis may 
assist in quantifying the rank order of treatments in terms of efficacy/tolerability and 
outcomes. The direct and indirect analyses revealed two treatments with better effectiveness 
compared to the reference treatment (EP) for the outcome ORR: 1) combination of Cisplatin, 
Cyclophosphamide, Etoposide and Epirubicin and 2) combination of Cisplatin, Doxorubicin 
and Etoposide with Vincristine (intensified), respectively. But, the former combination 
showed worst tolerability than EP.  
On the contrary, seven other regimens showed worse effectiveness for the ORR outcome 
(Cisplatin plus Doxorubicin plus Etoposide plus Vincristine (intensified), Ifosfamide plus 
Mesna, Carboplatin plus Pemetrexeb, Doxorubicin plus Etoposide plus Vincristine, 
Cyclophosphamide plus Doxorubicin plus Etoposide, Teniposide and Cisplatin) and three 
regimens for the both outcomes (ORR and CR) (Etoposide standard, Etoposide intensified 
and Carboplatin plus Ifosfamide).  
In the frequentist network analysis, possible effect modifiers were not taken into account and 
only the unadjusted pooled ORs were calculated since data that affect the response were not 
provided in the individual studies. In addition, the estimated effect sizes were unadjusted for 
treatment dosage levels. Nevertheless, the developed methodology (and of course, the NET-
MS system) cannot estimate adjusted effect sizes; though; it has the capability of subgroup 
analyses.  
With a frequentist approach, result of analysis is presented as a point estimate with a 95% CI. 
However, these CIs cannot be interpreted in terms of probabilities; this shortcoming could be 
overcome by the use of Bayesian methods which presents probabilities that can predict and is 
of relevance to the decision maker [25, 165]. These methods assume prior probability 
distribution, prior belief of possible values of model parameter based on what is already 
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known on the subject. Then in the light of observed data in the study, likelihood distribution 
of these parameters is used to obtain a corresponding posterior probability distribution. For 
NMA, specific advantage is that the posterior probability distribution allows calculating the 
probability of the competing interventions. Results are expressed in credible intervals as 
opposed to the CI in case of frequentist analysis. Other advantages of Bayesian meta-analysis 
include the straightforward way to make predictions and possibility to incorporate different 
sources of uncertainty [168]. 
We have performed the same analysis using Bayesian statistics and in principle we reached 
out to similar results.  
However, when we performed an adjusted analysis to ED-SCLC (12 studies, 5 interventions, 
3'961patients, and 10 possible pairwise comparisons_5 of those with direct data), it was 
revealed that the combination of platin plus paclitaxel might be a good first line option for 
achieving ORR (SUCRA 91%), followed by platin plus ambrubicin (73%), while the 
combination of platin plus etoposide provides the lowest probability of success (SUCRA 
15%).  
An additional analysis performed including some of the investigational treatments with 
available results until mid-2016; now the network was increased to 17 studies, comparing 11 
interventions, including 4'605 patients and 55 pairwise comparisons (12 of those with direct 
data). As it was expected, new treatments are improve the probabilities of achieving ORR in 
ED-SCLC, but not significantly differentiated from current standard of care and further 
investigation is needed to drive conclusions on how these treatments would be better utilized 
in clinical practice. 
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The applicability of previously mentioned analyses is questionable due to  several limitations; 
the differences of the dosage schemes and/or treatment cycle maximum duration were 
ignored since we focused to the antitumor activity of each treatment based on the mode of 
action of each chemotherapy agent (or combination of individual chemotherapy agents). We 
adopted this approach since the scientific evidence of the relative anti-tumor activity of each 
chemotherapy agent, or combination of individual chemotherapy agents is relative scarce.  
In addition, the existence of publication bias (defining as the differential magnitude of effect 
in large versus small studies) cannot totally be excluded [169]. However, a valid method for 
testing publication bias in network analysis does not exist. Also, in the network analysis, 
adjustments for multiple comparisons may not be applicable since the purpose of the analysis 
was to explore the relative significance of risk effect [170].  
Data were synthesized with an objective (to assess the relative effectiveness of treatments) 
but not with a pre-specified key hypothesis [170-172]. An appropriate multiple test 
adjustment is difficult or even impossible because the investigated comparisons in the 
network are not independent and a clear structure in the multiple tests is missing [172].  
Finally, the existence of false positive results may not be totally excluded since heterogeneity 
between studies within the network cannot be assessed (lack of valid methodology) and the 
network analysis cannot adjust for possible effect modifiers; though, synthesis of data from 
many studies usually is expected to reduce false discovery rate. 
Although the quality of reporting of the studies included in the network-analysis was 
assessed, a sensitivity analysis involving the studies with high reporting quality was not 
considered since the aim of the assessment was to obtain an indication of the reporting 
quality of the current evidence in SCLC treatment; in addition, there is no established quality 
scales to divide “high-quality” from “low-quality” studies. Furthermore, it has been shown 
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that individual quality measures are not associated with treatment effect size across studies 
and medical areas [173]. 
Also, the analysis was not restricted to specific subpopulations (e.g. limited and extensive-
stage SCLC) due to lack of replication and to achieve greater power in detecting significant 
results. Since the indirect comparisons are not randomized but observational studies across 
trials the differences in study populations and prognostic factors across RCTs may lead to 
overestimation of the treatment effects [1, 9]. 
In addition, the network analysis was based on grouped data from published RCTs and not on 
individual patient data, assuming that the relative effectiveness of a treatment is consistent in 
different RCTs. Therefore, the results regarding the superiority of a particular treatment 
should be interpreted with great caution. However, when the previous basic assumption may 
not be met, the results of one RCT can be not generalizable to another; though, the 
identification of factors that may influence the generalizability of an RCT is rather difficult 
[174].  
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Charter 8 – Conclusions 
In conclusion, network meta-analyses can be considered an extension of traditional meta-
analysis by including multiple different pairwise comparisons across a range of different 
interventions to allow multiple treatment comparisons in the absence of head-to-head 
evidence. Furthermore, the methodology can combine direct and indirect treatment 
comparisons, thereby synthesizing a greater share of the available evidence than a traditional 
meta-analysis 
It is essential to assess the internal validity (appropriate identification of studies that form the 
evidence network, quality of the individual RCTs, and extent of confounding bias due to 
similarity and consistency violations) and external validity (external validity of RCTs 
included in the evidence network) of the network , prior initiating an exercise. 
From methodological perspective, Bayesian and frequentist approaches should be 
complementary tools; if the user's approach to a clinical problem places an emphasis on 
identifying causal relationships, a frequentist approach might be best suited. On the other 
hand, if the user takes an approach in which estimating a priori probabilities is appropriate, a 
Bayesian approach might be more appropriate. Ideally both approaches should be used for the 
same study. 
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Appendices 
Supplementary Tables 
 
Supplementary Table 1: List of network meta-analyses in oncology reported 2006-2014 
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Part 2: rituximab for non-Hodgkin's lymphoma." J Clin Epidemiol 65(9): 996-
1009. 
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• Wang, S. Y., H. Chu, et al. (2012). "Network meta-analysis of margin threshold for 
women with ductal carcinoma in situ." J Natl Cancer Inst 104(7): 507-516. 
2013 • Bachelot, T., R. McCool, et al. (2014). "Comparative efficacy of everolimus plus 
exemestane versus fulvestrant for hormone-receptor-positive advanced breast 
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• Bakalos, G., M. Miligkos, et al. (2013). "Assessing the relative effectiveness and 
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• Dranitsaris, G., S. Schmitz, et al. (2013). "Small molecule targeted therapies for the 
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• Fang, Y., Y. Ding, et al. (2013). "Radioiodine therapy for patients with 
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• Palmieri, C., J. R. Fullarton, et al. (2013). "Comparative efficacy of 
bisphosphonates in metastatic breast and prostate cancer and multiple myeloma: a 
mixed-treatment meta-analysis." Clin Cancer Res 19(24): 6863-6872. 
• Pechlivanoglou, P., H. H. Le, et al. (2014). "Mixed treatment comparison of 
prophylaxis against invasive fungal infections in neutropenic patients receiving 
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• Robertson, C., A. Close, et al. (2013). "Relative effectiveness of robot-assisted and 
standard laparoscopic prostatectomy as alternatives to open radical prostatectomy 
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• Signorovitch, J., R. Ayyagari, et al. (2014). "Major molecular response during the 
first year of dasatinib, imatinib or nilotinib treatment for newly diagnosed chronic 
myeloid leukemia: a network meta-analysis." Cancer Treat Rev 40(2): 285-292. 
• Skoetz, N., S. Trelle, et al. (2013). "Effect of initial treatment strategy on survival 
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• Terasawa, T., N. A. Trikalinos, et al. (2013). "Comparative efficacy of first-line 
therapies for advanced-stage chronic lymphocytic leukemia: a multiple-treatment 
meta-analysis." Cancer Treat Rev 39(4): 340-349. 
 
 
• Zeppetella, G., A. Davies, et al. (2014). "A network meta-analysis of the efficacy 
of opioid analgesics for the management of breakthrough cancer pain episodes." J 
Pain Symptom Manage 47(4): 772-785 e775. 
2014 • Bachelot, T., R. McCool, et al. (2014). "Comparative efficacy of everolimus plus 
exemestane versus fulvestrant for hormone-receptor-positive advanced breast 
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Supplementary Table 2: The characteristics of the individual RCTs included in network meta-analysis for assessing the relative 
effectiveness of treatments in SCLC 
 
            Demographics Tumor 
Response 
Survival Common Hematologic Toxicities (Grade 3 & 4) 
  Author Year 
Published 
Country Stage Tx Randomized
Patients (n) 
Gender, 
male:female 
(%)  
Age, mo(s).
mean, ± 
SD or 
median, 
min-max) 
 OBR 
(%) 
OS, mo(s). 
(mean, ± SD 
or  median, 
min-max) 
Anemia 
(%) 
Leukopenia 
(%) 
Neutropenia 
(%) 
Thrombocytopenia 
(%) 
1 Abratt RP 1991 South 
Africa 
LD C1 40 65.0 : 35.0 58 (35-71) 75.0 14 (n.a.-
n.a.) 
        
C2 38 63.2 : 36.8 59 (33-72) 52.6 11 (n.a.-
n.a.) 
        
2 Abratt RP 1995 South 
Africa 
LD C1 43 65.1 : 34.9 59 (33-72) 74.4 14.5 (n.a.-
n.a.) 
  9.3     
C3 38 71.1 : 28.9 60 (35-71) 60.5 12 (n.a.-
n.a.) 
  28.9     
3 Altinbas M 2004 Turkey LD + 
ED 
C4 42 83.3 : 16.7 58 (37-75) 40.5 LD: 10 (7.3 
- 12.7),  
ED: 8 (6.1 - 
9.9) 
    2.4   
LD + 
ED 
C5 42 78.6 : 21.4 57.5 (34-
74) 
64.3% LD: 16 (8.3 
- 23.7),  
ED: 13 (9.8 
- 16.2) 
 
    11.9   
4 Ansari R 1995 USA ED C6 84 67.9 : 32.1 61 (45-76) 67.1 7.3 (n.a.-
n.a.) 
15.9 47.6   22.0 
C7 87 66.7 : 33.3 63 (32-78) 72.8 9.1 (n.a.-
n.a.) 
52.5 71.3   35.0 
5 Ardizzoni A 2002 Multi-
countries 
LD + 
ED 
C8 119 70.6 : 29.4 59 (33-69) 79.0 13.5 (11.8 - 
15.8) 
        
C9 125 70.4 : 29.6 59 (35-70) 88.2 13 (11.3 - 
15.3) 
  
 
 
 
 
      
Institutional R
epository - Library & Inform
ation Centre - University of Thessaly
26/03/2018 13:04:56 EEST - 137.108.70.6
110 
6 Artal-Cortes A 2004 Spain LD + 
ED 
C6 202 98.5 : 1.5 60 (39-75) 68.8 LD: 12.9 
(11.4 - 14.5), 
ED: 7.9 (7.0 
- 9.0) 
14.4   57.4 13.9 
C10 200 99.0 : 1.0 63 (35-75) 74.5 LD: 12.9 
(11.7 - 14.6), 
ED: 8.1 (6.8 
- 9.5) 
14.5   42.5 16.0 
7 Baka S 2008 UK ED C9 139 48.2 : 51.8 66 (38-81) 69.8 9.7 (n.a.-
n.a.) 
27.7   91.2 56.2 
C6 141 53.2 : 46.8 65 (39-89) 75.2 10.6 (n.a.-
n.a.) 
19.3   58.6 49.3 
8 Baka S 2010 Greece ED C11 183 88.0 : 12.0 63 (35-78) 51.4 10.9 (0.5 - 
86.2) 
13.1   55.7 19.7 
C12 181 94.5 : 5.5 64 (42-82) 55.2 9.8 (0.5 - 
86.1) 
11.6   54.7 23.2 
9 Bork E 1991 Sweden LD + 
ED 
C13 46 58.7 : 41.3 74 (70-82) 65.2 8.5 (n.a.-
n.a.) 
        
C14 48 68.8 : 31.2 73 (70-83) 70.8 11.3 (n.a.-
n.a.) 
        
10 Chahinian AP 1989 USA LD + 
ED 
C15 86 72.0 : 28.0   51.2 7.9 (n.a.-
n.a.) 
        
C16 103 68.0 : 32.0   67.0 9.3 (n.a.-
n.a.) 
        
C17 105 64.0 : 36.0   47.6 7.9 (n.a.-
n.a.) 
        
11 De Marinis  2005 Italy LD + 
ED 
C18 70 80.0 : 20.0 63 (52-71) 62.9 LD: 1 (11 - 
30),  
ED: 8 (1 - 
27) 
12.9 12.9 41.4 41.4 
C19 70 88.6 : 11.4 61 (48-75) 57.1 LD: 12 (4 - 
28), 
ED: 9 (1-23) 
10.0 4.3 24.3 27.1 
12 Eckardt JR 2006 Multi-
countries 
LD + 
ED 
C20 389 79.4 : 20.6 59.7 (± 9.1) 63.0 9.8 (9.4 - 
10.6) 
37.9 29.9 58.4 45.9 
C6 395 78.7 : 21.3 59.6 (± 9.6) 68.9 10.1 (9.3 - 
10.9) 
44.3 44.3 83.6 14.5 
13 Ettinger DS 1990 Multi-
countries 
ED C3 294 67.3 : 32.7   61.2 10.7 (n.a.-
n.a.) 
        
C82 283 67.5 : 32.5   64.0 11.5 (n.a.-
n.a.) 
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14 Ettinger DS 2002 USA ED C3 46 54.3 : 45.7 64 (36-79) 56.5 10.5 (n.a.-
n.a.) 
        
C21 43 60.5 : 39.5 61 (33-79) 48.8 10.8 (n.a.-
n.a.) 
        
C13 46 65.3 : 21.7 61 (37-79) 43.5 9.5 (n.a.-
n.a.) 
        
15 Fukuoka M 1997 Japan ED C22 31 96.8 : 3.2 61 (42-73) 83.9 14.8 (11.4-
22.7) 
        
C23 32 78.1 : 21.9 61 (44-73) 96.9 8.0 (6.1-
10.4) 
        
16 Furuse K 1998 Japan ED C23 114 85.1 : 14.9 64 (32-74) 85.1 11.6 (9.8-
12.7) 
86.8 83.3   72.8 
C24 113 82.3 : 17.7 64 (38-74) 76.1 10.9 (6.7-
12.0) 
41.6 82.3   25.7 
17 Girling DJ 1996 UK LD + 
ED 
C25 154 63.0 : 37.0   55.3 4.6 (n.a.-
n.a.) 
        
C26 156 62.8 : 37.2   53.7 4.7 (n.a.-
n.a.) 
        
18 Greco FA 2005 USA ED C27 60 65.0 : 35.0 60 (42-78) 78.3 10.6 (9.5-
12.0) 
13.3 70.0 81.7 48.3 
C28 60 48.3 : 51.7 62 (38-79) 48.3 9.1 (7.7-
10.4) 
10.0 60.0 65.0 15.0 
19 Grote T 2005 USA LD + 
ED 
C30 109 54.0 : 45.9 64.4 (± 8.7) 59.6 10.5 (n.a.-
n.a.) 
        
C6 115 55.7 : 44.3 63.2 (± 8.9) 55.7 10.4 (n.a.-
n.a.) 
        
20 Heigener DF 2009 Germany ED C31 37 64.9 : 35.1 60 (46-72) 62.2 11.2 (9.1-
15.2) 
18.9   70.3 29.7 
C32 40 77.5 : 22.5 61 (41-76) 80.0 11.9 (8.8-
14.7) 
32.5   37.5 62.5 
21 Hirsch FR 1987 Multi-
countries 
ED C33 89 73.0 : 27.0 61 (± n.a.) 68.5 5.8 (n.a.-
n.a.) 
        
C34 92 80.4 : 19.6 60 (± n.a.) 66.3 6.8 (n.a.-
n.a.) 
        
C35 88 65.9 : 34.1 62 (± n.a.) 73.9 8.3 (n.a.-
n.a.) 
        
22 Hirsch FR 2001 Denmark LD + 
ED 
C86 136 53.0 : 47.0 59 (34-69) 72.1 10.4 (n.a.-
n.a.) 
        
C87 134 63.0 : 37.0 59 (40-69) 71.6 9.8 (n.a.-
n.a.) 
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23 Hong WK 1989 USA LD + 
ED 
C3 126 81.0 : 19.0 61 (37-79) 54.0 LD: 13.8 
(0.5-65.5), 
ED: 7.8 
(0.3-67.8) 
        
C36 141 70.0 : 30.0 62 (39-78) 54.6 LD: 13.8 
(0.5-89.5), 
ED: 9.8 
(0.3-67.8) 
        
C37 86 71.0 : 29.0 62 (43-80) 43.0 LD: 10.3 
(0.5-65.5), 
ED: 7.3 
(0.2-80.7) 
        
24 James LE 1996 UK ED C38 89 64.0 : 36.0 63 (38 - 74) 44.9 5.8 (4.0-6.6)   4.5   2.2 
C24 78 65.4 : 34.6 63 (39 - 75) 58.9 6.4 (4.9-7.3)   20.5   2.7 
25 Joss RA 
(Annals of 
Oncology 6: 41-
48, 1995) 
1995 Switzerland ED C39 32 96.9 : 3.1 59 (n.a. - 
n.a.) 
28.1 4.9 (n.a.-
n.a.) 
        
C81 27 85.2 : 14.8 56 (n.a. - 
n.a.) 
63.0 8.7 (n.a.-
n.a.) 
        
26 Joss RA (2) 
(Annals of 
Oncology 6: 
157-166, 1995.) 
1995 Switzerland LD + 
ED 
C81 202 86.6 : 13.4 58 (n.a. - 
n.a.) 
88.4 13.5 (n.a.-
n.a.) 
        
C89 204 87.7 : 12.3 58 (n.a. - 
n.a.) 
87.4% 11.5 (n.a.-
n.a.) 
        
27 Kanitz E  1992 Multi-
countries 
ED C40 52 80.8 : 19.2 55 (33-69) 63.6 6.6 (± n.a.)   19.2     
C41 59 88.1 : 11.9 56 (33-70) 69.2 27.7 (± n.a.)   8.8     
28 Lassen U 1996 Multi-
countries 
LD + 
ED 
C84 160 58.7 : 41.3 61 (34-70) 62.5 11.2 (n.a.-
n.a.) 
  53.0   29.0 
C83 158 69.0 : 31.0 62 (36-70) 72.2 11.3 (n.a.-
n.a.) 
  58.0   27.0 
C88 157 59.9 : 40.1 63 (37-70) 64.3 9.8 (n.a.-
n.a.) 
  77.0   10.0 
29 Lee SM 2009 UK LD + 
ED 
C42 121 56.2 : 43.8 62 (37-80) 62.8 8 (n.a.-n.a.) 14.0 31.4 38.8 21.5 
C6 120 56.7 : 43.3 62,5 (27-
81) 
62.5 8,1 (n.a.-
n.a.) 
2.5 13.3 28.3 4.2 
30 Leyvraz S 2008 Multi-
countries 
LD + 
ED 
C43 69 75.4 : 24.6   78.3 18.1 (n.a.-
n.a.) 
        
C44 71 71.8 : 28.2   67.6 14.4 (n.a.-
n.a.) 
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31 Lorigan P 2005 UK ED C44 159 67.3 : 32.7 58 (36-73) 76.1 13.9 (12.9-
15.8) 
45.8 95.4   82.5 
C43 159 59.1 : 40.9 58 (35-70) 84.3 14.4 (12.7-
16.0) 
71.5 94.7   95.3 
32 Lowenbraun S  
 
 
 
 
 
1984 USA ED C3 106 75.5 : 24.5   71.7 10.5 (n.a.-
n.a.) 
        
C45 108 75.9 : 24.1   74.1 10.6 (n.a.-
n.a.) 
        
33 Lyss  
  
  
2002 
  
  
USA ED C20 12 83.3 : 16.7 60.8 (± 8.5) 41.6 5.7 (n.a.-
n.a.) 
        
C28 13 46.2 : 53.8 64.7 (± 7.9) 53.8 13.8  (n.a.-
n.a.) 
        
C29 32 53.1 : 46.9 58.0 (± 
11.1) 
68.8 9.9 (n.a.-
n.a.) 
        
34 Mavroudis D 2001 Greece LD + 
ED 
C91 62 93.5 : 6.5 62 (36-75) 50.0 LD: 14 (0.5-
24.0), 
ED: 7 (0.5-
27.0) 
3.2   43.5 17.7 
C6 71 90.1 : 9.9 64 (37-75) 47.9 LD: 12.5 
(1.0-25.0), 
ED: 9.5 
(1.0-30.0) 
9.8   39.4 5.6 
35 Miller AA 1995 USA ED C6 156 63.5 : 36.5   53.8 9.5 (8.4-
11.0) 
32.0 62.0 85.0 32.0 
C46 150 74.7 : 25.3   60.0 9.9 (7.9-
11.2) 
55.0 83.0 83.0 52.0 
36 Milroy R 1993 UK LD + 
ED 
C47 111 55.9 : 44.1 59 (35-70) 72.1 10.3 (9.0-
12.0) 
        
C45 109 59.6 : 40.4 59 (37-69) 70.6 11 (9.0-12.3)         
37 Miyomoto H 1992 Japan LD + 
ED 
C6 42 76.2 : 23.8 63 (40-78) 66.7 13.8 (n.a.-
n.a.) 
19.0 42.9 21.4   
C7 47 76.6 : 23.4 63 (37-76) 59.6 14 (n.a.-
n.a.) 
36.2 72.3 25.5   
38 Monnet I 1992 France ED C48 30 96.7 : 3.3 58 (± n.a.) 75.9 9.7 (n.a.-
n.a.) 
        
C49 30 86.7 : 13.3 57 (± n.a.) 28.6 10.4 (n.a.-
n.a.) 
        
39 Murray N 1999 Multi-
countries 
ED C22 110 69.1 : 30.9 59.3 (± 
n.a.) 
87.1 11.8 (n.a.-
n.a.) 
        
C24 109 63.3 : 36.7 59.3 (± 
n.a.) 
69.7 10.9 (n.a.-
n.a.) 
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40 Nagel S 2011 Germany LD + 
ED 
C32 36 77.8 : 22.2 61 (± n.a.) 72.2 11 (6.9-15.0)   11.1   27.8 
C31 36 63.9 : 36.1 59 (± n.a.) 66.7 11 (4.2-17.7)   16.7   25.0 
41 Niell HB 2005 USA ED C6 282 46.1 : 53.9 62 (n.a.-
n.a.) 
65.6 9.9 (9.2-
10.8) 
17.4 34.4 66.7 13.8 
C91 283 45.2 : 54.8 61 (n.a.-
n.a.) 
73.1 10.6 (9.9-
11.2) 
19.8 40.3 44.5 22.3 
42 Noda K 2002 Japan ED C6 77 89.6 : 10.4 63 (41-70) 67.5 9.4 (8.1-
10.8) 
29.9 51.9 92.2 18.2 
C50 77 81.8 : 18.2 63 (33-70) 84.4 12.8 (11.7-
15.2) 
26.0 26.0 63.6 5.2 
43 Okamoto H 2007 Japan ED C31 110 86.4 : 13.6 74 (56-86) 72.7 10.6 (n.a.-
n.a.) 
29.1 53.6 94.5 55.5 
C6 110 89.1 : 10.9 73.5 (55-
85) 
73.4 9.9 (n.a.-
n.a.) 
24.8 51.4 89.9 15.6 
44 Postmus PE 1992 Multi-
countries 
LD + 
ED 
C8 63 77.8 : 22.2 59 (39-70) 83.3 12.3 (n.a.-
n.a.) 
  41.6   16.6 
C51 55 83.6 : 16.4 59 (38-69) 76.5 9.3 (n.a.-
n.a.) 
  52.9   49.0 
C49 60 78.3 : 21.7 57 (39-70) 60.3 10.5 (n.a.-
n.a.) 
  6.8   18.9 
45 Postmus PE 1996 Multi-
countries 
ED C8 73 84.9 : 15.1 61 (41-73) 68.5 7.6 (n.a.-
n.a.) 
11.0 90.4   20.5 
C85 70 78.6 : 21.4 61 (29-74) 70.0 8.7 (n.a.-
n.a.) 
32.9 90.0   62.9 
46 Pujol JL 2001 France ED C6 109 77.1 : 22.9 59.3 (± 8.9) 60.6 9.3 (n.a.-
n.a.) 
18.0   85.0 18.0 
C52 117 83.5 : 14.5 58.5  (± 
9.2) 
76.1 10.5 (n.a.-
n.a.) 
51.0   99.0 78.0 
47 Quoix E 2005 Multi-
countries 
ED C20 41 70.7 : 29.3 61 (± n.a.) 63.4 10.4 (1.0-
24.3) 
46.3 46.3 87.8 31.7 
C53 41 68.3 : 31.7 61 (± n.a.) 61.0 10.9 (0.4-
21.9) 
19.5 65.9 87.8 19.5 
48 Reck M 2003 Germany LD + 
ED 
C54 307 76.0 : 24.0 60 (35-75) 69.4 11.7 (10.9-
12.6) 
        
C55 301 75.0 : 25.0 60 (30-75) 72.1 12.7 (11.2-
14.1) 
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49 Roth BJ 1992 USA LD + 
ED 
C6 159 77.4 : 22.6 62.7 (± 
n.a.) 
60.7 8.6 (n.a.-
n.a.) 
25.0 29.3   9.3 
C3 156 80.1 : 19.9 61.7 (± 
n.a.) 
50.7 8.3 (n.a.-
n.a.) 
12.9 42.9   3.6 
C24 162 75.3 : 24.7 62.6 (± 
n.a.) 
59.4 8.1 (n.a.-
n.a.) 
26.1 39.9   16.7 
50 Rowland KM 1996 USA LD + 
ED 
C56 122 56.0 : 44.0   68.0           
C6 121 64.0 : 36.0   79.3           
51 Ruotsalainen 
TM 
1999 Multi-
countries 
LD + 
ED 
C6 78 59.0 : 41.0 60.5 (± 
n.a.) 
60.3 10.2 (n.a.-
n.a.) 
        
C57 75 64.0 : 36.0 59.6 (± 
n.a.) 
58.7 10.0 (n.a.-
n.a.) 
        
C58 66 66.7 : 33.3 59.9 (± 
n.a.) 
60.6 10.1 (n.a.-
n.a.) 
        
52 Schmittel A 2006 Germany ED C59 35 71.4 : 28.6 59 (34-77) 62.9   14.3 31.4 25.7 31.4 
C31 35 71.4 : 28.6 63 (48-74) 57.1   34.3 65.7 51.4 31.4 
53 Sculier JP 1990 Belgium LD + 
ED 
C60 95 89.5 : 10.5 61 (37-75) 74.1 11.3 (n.a.-
n.a.) 
  45.0   7.1 
C61 106 90.6 : 9.4 62 (35-74) 55.1 10.0 (n.a.-
n.a.) 
  34.7   7.1 
54 Sculier JP 1993 Belgium LD + 
ED 
C90 107 89.7 : 10.3 61 (35-74) 67.3 12.3 (n.a.-
n.a.) 
  58.9   6.5 
C8 108 89.8 : 10.2 61 (33-74) 61.4 10.8 (n.a.-
n.a.) 
  75.9   16.6 
55 Sculier JP 2001 Belgium ED C62 78 89.7 : 10.3 61 (37-75) 57.9 9.5 (7.8-
11.6) 
  84.6   15.4 
C63 78 83.3 : 16.7 64 (35-74) 73.6 8.8 (7.3-
10.2) 
  84.6   44.9 
56 Seifart U 2007 Germany ED C66 51 66.7 : 33.3 60.8 (± 
n.a.) 
78.4 11.8 (n.a.-
n.a.) 
21.6 27.5   19.6 
C67 49 67,3 : 32.7 63.8 (± 
n.a.) 
73.5 11.6 (n.a.-
n.a.) 
22.4 20.4   22.4 
57 Seifart U 2005 Germany ED C64 42 78.6 : 21.4 61.5 (40-
72) 
38.1 8.7 (n.a.-
n.a.) 
42.9 64.3   52.4 
C65 42 81.0 : 19.0 60.5 (37-
72) 
31.0 7.6 (n.a.-
n.a.) 
21.4 47.6   
 
 
 
 
40.5 
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58 Sekine I 2003 Japan ED C68 30 90.0 : 10.0 64 (47-70) 83.3 8.9 (n.a.-
n.a.) 
56.7 50.0 56.7 26.7 
C69 30 90.0 : 10.0 63 (46-68) 76.7 12.9 (n.a.-
n.a.) 
46.7 53.3 86.7 10.0 
59 Sekine I 2008 Japan ED C50 54 79.6 : 20.4 63 (42-70) 75.9 12.4 (n.a.-
n.a.) 
33.3 18.5 51.9% 3.7 
C70 55 85.5 : 14.5 62 (48-70) 87.3 13.7 (n.a.-
n.a.) 
45.5 52.7 94.5% 23.6 
60 Slevin ML 1989 UK ED C71 20     10.0           
C14 19     89.5           
61 Socinski MA 2009 Multi-
countries 
ED C72 453 71.7 : 28.3 62.5 (35.0-
88.5) 
24.9 8.1 (n.a.-
n.a.) 
10.8 4.0 10.2 9.1 
C31 455 72.5 : 27.5 62.5 (38.5 - 
86.5) 
44.0 10.6 (n.a.-
n.a.) 
7.3 8.1 46.2 10.1 
62 Socinski MA 2006 USA ED C72 38 42.1 : 57.9 66 (47-75) 39.5 10.4 (n.a.-
n.a.) 
11.4   17.1 14.3 
C73 40 50.0 : 50.0 66 (46.82) 35.0 7.6 (n.a.-
n.a.) 
5.3   18.4 21.1 
63 Souhami RL 1994 UK LD + 
ED 
C74 221 64.3 : 35.7 62 (34-73) 82.4 9.6 (n.a.-
n.a.) 
        
C24 217 67.7 : 32.3 63 (32-74) 81.1 8.8 (n.a.-
n.a.) 
        
64 Souhami RL 1997 UK LD + 
ED 
C38 80 52.5 : 47.5 67 (49-80) 46.3 5.9 (n.a.-
n.a.) 
        
C14 75 56.0 : 44.0 66 (50-86) 32.8 4.8 (n.a.-
n.a.) 
        
65 Steward WP 1998 Multi-
countries 
LD + 
ED 
C75 153 73.9 : 26.1 59 (38-75) 64.1 11.7 (n.a.-
n.a.) 
        
C76 147 73.5 : 26.5 60 (37-75) 77.6 14.8 (n.a.-
n.a.) 
        
66 Urban T 1999 France LD + 
ED 
C8 228 91.7 : 8.3 57 (± 9) 52.2 8.9 (7.9-9.3)         
C77 229 92.1 : 7.9 56 (± 10) 72.1 9.0 (8.2-
10.1) 
        
67 Wampler GL  1991 USA ED C3 79 65.4 : 34.6   43.0           
C78 82 69.8 : 30.2   48.8     
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68 White SC 2001 UK ED C3 59 57.6 : 42.4 70 (46-85) 37.9 4.3 (n.a.-
n.a.) 
8.6 27.6   3.4 
C79 60 48.3 : 51.7 70 (54-76) 25.4 3.9 (n.a.-
n.a.) 
16.9 25.4   27.1 
69 Wolf M 1987 Germany LD + 
ED 
C6 72 89.0 : 11.0 57 (35-70) 65.3 11.6 (n.a.-
n.a.) 
        
C80 64 91.0 : 9.0 57 (25-71) 68.8 9.4 (n.a.-
n.a.) 
        
70 Woll PJ 2001 UK LD + 
ED 
C44 25 80.0 : 20.0 61 (40-69) 76.0 11.8 (n.a.-
n.a.) 
        
C43 25 56.0 : 44.0 55 (47-68) 80.0 12.7 (n.a.-
n.a.) 
        
71 Zatloukal P 2010 Multi-
countries 
ED C50 202 76.2 : 23.8 60 (34-79) 39.1 10.2 (9.0-
11.7) 
6.9 6.4% 5.4 38.1 
C6 203 76.4 : 23.6 61 (40-75) 46.3 9.7 (8.9-
11.1) 
6.4 9.9 4.4 59.6 
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Supplementary Table 3: Quality assessment of of the individual RCTs included in 
network meta-analysis for assessing the relative effectiveness of treatments in SCLC 
  Author Year 
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1 Abratt RP 1991 South 
Africa 
LD Yes Yes No Yes No n.a. Yes 
2 Abratt RP 1995 South 
Africa 
LD Yes Yes No Yes No n.a. Yes 
3 Altinbas M 2004 Turkey LD + 
ED 
 
Yes Yes Yes Yes No n.a. Yes 
4 Ansari R 1995 USA ED Yes Yes No Yes No n.a. Yes 
5 Ardizzoni A 2002 Multi-
countries 
LD + 
ED 
Yes Yes Yes Yes No n.a. Yes 
6 Artal-Cortes A 2004 Spain LD + 
ED 
Yes Yes Yes Yes No n.a. Yes 
7 Baka S 2008 UK ED Yes Yes Yes Yes No n.a. Yes 
8 Baka S 2010 Greece ED Yes Yes Yes No No n.a. Yes 
9 Bork E 1991 Sweden LD + 
ED 
Yes Yes Yes No No n.a. Yes 
10 Chahinian AP 1989 USA LD + 
ED 
Yes Yes Yes No No n.a. Yes 
11 De Marinis  2005 Italy LD + 
ED 
Yes Yes Yes No No n.a. Yes 
12 Eckardt JR 2006 Multi-
countries 
LD + 
ED 
Yes Yes Yes No No n.a. Yes 
13 Ettinger DS 1990 Multi-
countries 
ED Yes No Yes No No n.a. No 
14 Ettinger DS 2002 USA ED Yes Yes Yes No No n.a. Yes 
15 Fukuoka M 1997 Japan ED Yes Yes No No No n.a. Yes 
16 Furuse K 1998 Japan ED Yes Yes Yes No No n.a. Yes 
17 Girling DJ 1996 UK LD + 
ED 
Yes Yes Yes No No n.a. Yes 
18 Greco FA 2005 USA ED Yes Yes Yes No No n.a. Yes 
19 Grote T 2005 USA LD + 
ED 
Yes Yes Yes No No No Yes 
20 Heigener DF 2009 Germany ED Yes Yes Yes No No n.a. Yes 
21 Hirsch FR 1987 Multi-
countries 
ED Yes Yes No No No n.a. No 
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22 Hirsch FR 2001 Denmark LD + 
ED 
Yes Yes Yes No No n.a. Yes 
23 Hong WK 1989 USA LD + 
ED 
Yes No Yes No No n.a. Yes 
24 James LE 1996 UK ED Yes No Yes Yes No n.a. Yes 
25 Joss RA (Annals 
of Oncology 6: 
41-48, 1995) 
1995 Switzerland ED Yes No Yes No No n.a. Yes 
26 Joss RA (2) 
(Annals of 
Oncology 6: 157-
1995 Switzerland LD + 
ED 
Yes Yes Yes Yes No n.a. Yes 
27 Kanitz E  1992 Multi-
countries 
ED Yes Yes No No No n.a. Yes 
28 Lassen U 1996 Multi-
countries 
LD + 
ED 
Yes No No No No n.a. Yes 
29 Lee SM 2009 UK LD + 
ED 
Yes Yes Yes Yes No n.a. Yes 
30 Leyvraz S 2008 Multi-
countries 
LD + 
ED 
Yes Yes Yes No No n.a. Yes 
31 Lorigan P 2005 UK ED Yes Yes Yes Yes No n.a. Yes 
32 Lowenbraun S  1984 USA ED Yes No Yes No No n.a. Yes 
33 Lyss  2002 USA ED Yes Yes Yes Yes Yes n.a. Yes 
34 Mavroudis D 2001          
35 Miller AA 1995 USA ED Yes Yes Yes Yes No n.a. Yes 
36 Milroy R 1993 UK LD + 
ED 
Yes No Yes Yes No n.a. Yes 
37 Miyomoto H 1992 Japan LD + 
ED 
Yes No No No No n.a. Yes 
38 Monnet I 1992 France ED Yes No Yes No No n.a. Yes 
39 Murray N 1999 Multi-
countries 
ED Yes Yes Yes No No n.a. Yes 
40 Nagel S 2011 Germany LD + 
ED 
Yes Yes Yes Yes Yes n.a. Yes 
41 Niell HB 2005 USA ED Yes Yes No No No n.a. Yes 
42 Noda K 2002 Japan ED Yes Yes Yes No No n.a. Yes 
43 Okamoto H 2007 Japan ED Yes Yes Yes No No n.a. Yes 
44 Postmus PE 1992 Multi-
countries 
LD + 
ED 
Yes No No No No n.a. Yes 
45 Postmus PE 1996 Multi-
countries 
ED Yes No Yes Yes No n.a. Yes 
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46 Pujol JL 2001 France ED Yes No Yes Yes No n.a. Yes 
47 Quoix E 2005 Multi-
countries 
ED Yes Yes Yes Yes No n.a. Yes 
48 Reck M 2003 Germany LD + 
ED 
Yes Yes Yes Yes No n.a. Yes 
49 Roth BJ 1992 USA LD + 
ED 
Yes Yes Yes No No n.a. Yes 
50 Rowland KM 1996 USA LD + 
ED 
Yes No Yes No No n.a. Yes 
51 Ruotsalainen TM 1999 Multi-
countries 
LD + 
ED 
Yes Yes Yes No No n.a. Yes 
52 Schmittel A 2006 Germany ED Yes Yes Yes Yes No n.a. Yes 
53 Sculier JP 1990 Belgium LD + 
ED 
Yes No No No No n.a. No 
54 Sculier JP 1993 Belgium LD + 
ED 
Yes No No No No n.a. No 
55 Sculier JP 2001 Belgium ED Yes No No No No n.a. No 
56 Seifart U 2007 Germany ED Yes Yes Yes Yes No n.a. Yes 
57 Seifart U 2005 Germany ED Yes Yes Yes Yes No n.a. Yes 
58 Sekine I 2003 Japan ED Yes Yes Yes Yes No n.a. Yes 
59 Sekine I 2008 Japan ED Yes No No Yes No n.a. Yes 
60 Slevin ML 1989 UK ED Yes No No No No n.a. Yes 
61 Socinski MA 2009 Multi-
countries 
ED Yes Yes Yes Yes No n.a. Yes 
62 Socinski MA 2006 USA ED Yes Yes Yes Yes No n.a. Yes 
63 Souhami RL 1994 UK LD + 
ED 
Yes Yes Yes Yes No n.a. Yes 
64 Souhami RL 1997 UK LD + 
ED 
Yes Yes Yes Yes No n.a. Yes 
65 Steward WP 1998 Multi-
countries 
LD + 
ED 
Yes Yes Yes No No n.a. Yes 
66 Urban T 1999 France LD + 
ED 
Yes Yes Yes Yes No n.a. Yes 
67 Wampler GL  1991 USA ED Yes No No No No n.a. Yes 
68 White SC 2001 UK ED Yes Yes Yes Yes No n.a. Yes 
69 Wolf M 1987 Germany LD + 
ED 
Yes No No No No n.a. Yes 
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70 Woll PJ 2001 UK LD + 
ED 
Yes No No No No n.a. Yes 
71 Zatloukal P 2010 Multi-
countries 
ED Yes Yes Yes Yes No n.a. Yes 
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Supplementary Table 4: Proportion of reporting of 24 data items in a total of 81 randomized clinical trials in small cell lung cancer by 
publication period (pre- and post-CONSORT and combined)* 
Data items Combined 
1984-2011 
(n = 71)† 
Pre-
CONSORT 
1984-1995 
(n = 24) 
Post-
CONSORT 
1996-2011 
(n = 47) 
ΔPost-
CONSORT – 
Pre-
CONSORT 
OR, 95% CI ¥ P-value‡ 
FET Two-
tailed 
TITLE/ABSTRACT 
1. Randomizedintitle/abstract 0.83 (59) 0.83 (20) 0.83 (39) 0.95 (19) 0.9750 (0.2616 
– 3.6342) 
1.0000 
INTRODUCTION 
2. Scientific background in introduction 0.89 (63) 0.83 (20) 0.91 (23) 0.65 (13) 2.150 (0.4875 -  
9.4826) 
0.4296 
METHODS 
3. Eligibility criteria for participants 1.00 (71) 1.00 (24) 1.00 (47) 0.54 (13) NaN 1.0000 
 
4. Precise details of the interventions in each arm 1.00 (71) 1.00 (24) 1.00 (47) 0.54 (13) NaN 1.0000 
 
5. Objectives 0.92 (65) 0.88 (21) 0.94 (44) 0.62 (13) 2.095 (0.389 – 
11.272) 
0.3992 
6. End-points 0.68 (48) 0.46 (11) 0.79 (37) 2.36 (26) 4.373 (1.508 – 
12.676) 
0.0075 
7. Sample size 0.76 (54) 0.54 (13) 0.93 (41) 2.15 (28) 5.782 (1.787 – 
18.708) 
0.0033 
8. Method of randomization (sequence generation) 0.45 (32) 0.29 (7) 0.53 (25) 2.57 (18) 0.760 (0.965 – 
7.888) 
0.0778 
 
9. Allocationconcealment 0.04 (3) 0.04 (1) 0.04 (2) 1.0 (1) 1.022 (0.088 – 
11.876) 
1.0000 
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10. Implementation of randomization 0.01 (1) 0.00 (0) 0.02 (1) n.a. (1) 0 1.0000 
11. Blinding (masking) 0.00 (0) n.a. 0.00 (0/2) n.a. (0) n.a. n.a. 
12. Statisticalmethods 0.90 (64) 0.79 (19) 0.96 (45) 1.36 (26) 5.921 (1.055 – 
33.242) 
0.0396 
RESULTS 
13. Participant flow 0.93 (66) 0.83 (20) 0.99 (46) 1.30 (26) 9.200 (0.966 – 
87.580) 
0.0416 
14. Periods: a. Recruitment 0.61 (43) 0.33 (8) 0.74 (35) 3.38 (27) 5.833 (1.996 – 
17.048) 
0.0017 
b. Follow-up 0.01 (1) 0.00 (0) 0.02 (1) n.a. (1) 0 1.0000 
15. Baseline data 0.97 (69) 1.00 (24) 0.96 (45) 0.92 (22) Infinity 0.5461 
16. "Intention-to-treat" analysis 0.82 (58) 0.67 (16) 0.89 (42) 1.63 (26) 4.200 (1.195 – 
14.763) 
0.0264 
17. a. Outcomes and 0.69 (49) 0.63 (15) 0.72 (34) 1.27 (19) 1.569 (0.552 – 
4.461) 
0.2597 
b. Estimation of effects 0.32 (23) 0.13 (3) 0.43 (20) 5.66 (17) 5.185 (1.357 – 
19.819) 
0.0150 
18. Ancillary analyses 0.54 (38) 0.33 (8) 0.64 (30) 2.75 (22) 3.529 (1.252 – 
9.951) 
0.0231 
19. Adverseevents 0.77 (55) 0.63 (15) 0.85 (40) 1.66 (25) 3.429 (1.083 – 
10.8532) 
0.0397 
DISCUSSION 
20. Interpretation of the results 0.80 (57) 0.83 (20) 0.79 (37) 0.85 (17) 0.740 (0.206 – 
2.664) 
0.7594 
21. Generalizability 0.76 (54) 0.63 (15) 0.83 (39) 1.60 (24) 2.925 (0.951 – 
8.994) 
0.0784 
22. Overallevidence 0.68 (48) 0.50 (12) 0.77 (36) 2.00 (24) 3.2727 (1.1487 
– 9.3241) 
0.0327 
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* CONSORT = Consolidated Standards of Reporting Trials. 
† The percentage of articles reporting the CONSORT item.  
¥ Odds ratio of reporting an item at post-CONSORT period relative to pre-CONSORT. 
‡ P-values from Fisher's exact test for testing the association between reporting an item and publication period.
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Supplementary Table 5: Definition of treatments 
No Description of regimen 
C1 Doxorubicin + Etoposide + Vincristine (intensified)  
C2 Doxorubicin  + Etoposide + Vincristine  
C3 Cyclophosphamide + Doxorubicin  + Vincristine  
C4 Cyclophosphamide  + Epirubicine + Vincristine  
C5 Cyclophosphamide + Epirubicin + Vincristine + Low Molecular Weight Heparin  
C6 Cisplatin + Etoposide  
C7 Cisplatin + Etoposide + Ifosfamide  
C8 Cyclophosphamide + Doxorubicin + Etoposide 
C9 Cyclophosphamide + Doxorubicin  + Etoposide (intesified) 
C10 Cisplatin + Epirubicin  
C11 Cisplatin + Etoposide / Topotecan (sequental adm.: 4 cycles of EP followed by 4 
cycles of T) 
C12 Topotecan  \ Cisplatin + Etoposide (alternate adm.: alternating cycles of EP and 
T) 
C13 Teniposide  
C14 Etoposide  
C15 CCNU + Cyclophosphamide + Doxorubicin  + Methotrexate  
C16 CCNU  + Cyclophosphamide + Doxorubicin  + Methotrexate + Warfarin 
C17 Cisplatin+ Etoposide + Hexamethylamine + Mitomycin / CCNU + 
Cyclophosphamide  + Doxorubicin + Methotrexate (alternating administration) 
C18 Cisplatin + Etoposide  + Gemcitabin  
C19 Cisplatin + Gemcitabin  
C20 Cisplatin + Topotecan  
C21 Ifosfamide + MESNA  
C22 Cisplatin + Doxorubicin + Etoposide + Vincristine  
C23 Cisplatin + Doxorubicin  + Etoposide + Vincristine  (intesified) 
C24 Cisplatin + Etoposide / Cyclophosphamide  + Doxorubicin + Vincristine ; (alt. 
administration) 
C25 Cyclophosphamide  + Etoposide + Methotrexate+ Vincristine  
C26 Etoposide  + Vincristine  
C27 Etoposide  + Carboplatin+ Paclitaxel  
C28 Paclitaxel + Topotecan  
C29 Paclitaxel + Topotecan (intesified) 
C30 Cisplatin + Etoposide (intesified) 
C31 Carboplatin + Etoposide  
C32 Carboplatin + Etoposide (intensified) 
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C33 CCNU + Cyclophosphamide +Vincristine + Methotrexate  
C34 CCNU + Cyclophosphamide + Vincristine + Etoposide (delayed administration of 
etoposide) 
C35 CCNU + Cyclophosphamide + Vincristine + Etoposide  
C36 Cyclophosphamide + Etoposide + Vincristine  
C37 Cyclophosphamide + Vincristine  
C38 Cisplatin  + Etoposide / Cyclophosphamide + Doxorubicin + Vincristine 
(intensified) 
C39 Carboplatin + Teniposide  
C40 Cisplatin  + Doxorubicin 
C41 Doxorubicin + Cyclophosphamide  
C42 Carboplatin + Gemcitabin  
C43 Carboplatin + Etoposide + Ifosfamide + Mesna (intensified) 
C44 Carboplatin + Etoposide + Ifosfamide + Mesna 
C45 Cyclophosphamide + Doxorubicin  + Etoposide + Vincristine  
C46 Cisplatin + Etoposide (per os administration) 
C47 Cyclophosphamide + Doxorubicin + Etoposide  + Vincristine + Verapamil  
C48 Cisplatin + Doxorubicin + Etoposide  
C49 Carboplatin + Ifosfamide + Vincristine  
C50 Cisplatin + Irinotecan  
C51 Carboplatin + Ifosfamide 
C52 Cisplatin + Cyclophosphamide + Etoposide + Epirubicin 
C53 Cisplatin + Topotecan(intensified iii) 
C54 Carboplatin + Etoposide + Vincristine  
C55 Carboplatin + Etoposide + Paclitaxel  
C56 Cisplatin + Etoposide + Megestrol acetate 
C57 Cisplatin + Etoposide + nIFNA-a  
C58 Cisplatin + Etoposide + rIFNA-a 
C59 Carboplatin + Irinotecan  
C60 Cisplatin + Etoposide + Vindesine  
C61 Etoposide + Vindesine  
C62 Epirubicin + Ifosfamide + Vindensine  
C63 Epirubicin + Ifosfamide + Vindensine (intensified) 
C64 Cisplatin + Topotecan (intensified i) 
C65 Cisplatin + Topotecan (intensified ii)  
C66 Carboplatin + Topotecan (intensified) 
C67 Carboplatin + Topotecan  
C68 Cisplatin + Etoposide + Irinotecan (intensified i) 
C69 Cisplatin + Etoposide + Irinotecan (intensified ii) 
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C70 Cisplatin + Etoposide + Irinotecan  
C71 Etoposide (intesified) 
C72 Carboplatin + Pemetrexeb  
C73 Cisplatin + Pemetrexeb  
C74 Cisplatin + Etoposide / Doxorubicin + Ifosfamide; (alternating cycles) 
C75 Carboplatin + Etoposide + Ifosfamide + Vincristine  
C76 Carboplatin + Etoposide + Ifosfamide + Vincristine  (intensified) 
C77 Cisplatin  + Cyclophosphamide  + Doxorubicin  + Etoposide  
C78 Cyclophosphamide + Doxorubicin + Vincristine / Cisplatin + Etoposide + 
Methotrexate (alternated every 3 weeks) 
C79 Cisplatin  
C80 Etoposide + Ifosfamide  
C81 Doxorubicin+ Cisplatin+ Etoposide /CCNU + Cyclophosphamide + Methotrexate 
+ Vincristine  
C82 Cyclophosphamide + Doxorubicin + Vincristine / Etoposide+ Hexamethylamine 
+ Methotrexate; (alt. administration) 
C83 Carboplatin + Teniposide + Vincristine  for cycles 1-3, 7,11 / Cyclophosphamide 
+ CCNU + Vincristine + Etoposide for cycles 4,8 / Doxorubicin + Vincristine for 
cycles 5,9 / Cisplatin  + Hexamethylmelamine + Vindesine for cycles 6,10  
C84 Cisplatin + Teniposide + Vincristine for cycles 1-3, 7,11 / Cyclophosphamide + 
CCNU + Vincristine + Etoposide for cycles 4,8 / Doxorubicin + Vincristine for 
cycles 5,9 / Cisplatin + Hexamethylmelamine + Vindesine for cycles 6,10  
C85 Cyclophosphamide + Doxorubicin + Etoposide for cycles 1,3,5 / Carboplatin + 
Ifosfamide (+ Vincristine for cycles 2,4  
C86 Carboplatin + Cisplatin + Teniposide for cycles 1-3, 6  /  Cyclophosphamide + 
Messnafor cycle 4 / Epirubicin for cycle 5 
C87 Carboplatin + Teniposide  for cycles 1-3, 6  /  Cyclophosphamide + Messna  for 
cycle 4 / Epirubicin for cycle 5 
C88 Cyclophosphamide+ CCNU + Vincristine  + Etoposide  for cycles 1,4,7,10/ 
Doxorubicin  + Vincristine for cycles 2,5,8,11/ Cisplatin + Hexamethylmelamine 
+ Vindesine  for cycles 3,6,9 
C89 Doxorubicin+ Cisplatin + Etoposide  for cycles 1-3 / CCNU + Cyclophosphamide 
+ Methotrexate  + Vincristine for cycles 4-6 
C90 Doxorubicin + Cisplatin + Cyclophosphamide  + Etoposide + Methotrexate + 
Vincristine  + Vindesine  
C91 Cisplatin + Etoposide + Paclitaxel  
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Supplementary Table 6: Results of all direct and indirect comparisons 
Type of analysis 
(D=Direct, 
I=Indirect) 
Treatment Comparator OR 95LL 95UL 
Patients with objective response rate 
D C56 C6 0.55422 0.309755 0.991621 
D C3 C6 0.665814 0.414409 1.06974 
D C46 C6 1.28571 0.816817 2.02377 
D C50 C6 0.593876 0.132406 2.66369 
D C30 C6 1.1772 0.692344 2.00161 
D C31 C6 1.27801 0.510157 3.20158 
D C9 C6 2.35832 0.093697 59.3584 
D C52 C6 3.38354 0.033455 342.2 
D C20 C6 0.459808 0.023609 8.95511 
D C42 C6 1.2746 0.455121 3.56961 
D C80 C6 1.14231 0.542099 2.40707 
D C57 C6 0.890407 0.404427 1.96037 
D C91 C6 1.08538 0.543949 2.16574 
D C24 C6 0.947479 0.586228 1.53134 
D C7 C6 1.05174 0.599475 1.84521 
D C58 C6 0.974952 0.481172 1.97545 
D C10 C6 0.983117 0.402191 2.40313 
I C13 C6 0.347879 0.213037 0.568071 
I C79 C6 0.333012 0.180685 0.613757 
I C23 C6 3.7901 1.76812 8.1244 
I C21 C6 0.429696 0.26345 0.700848 
I C14 C6 0.403549 0.237971 0.684336 
I C71 C6 0.005622 6.93E-05 0.456306 
I C2 C6 0.398636 0.169074 0.939889 
I C22 C6 1.59698 0.652116 3.9109 
I C48 C6 5.90883 0.13127 265.972 
I C51 C6 10.1892 0.048849 2125.34 
I C32 C6 1.66141 0.425502 6.48715 
I C27 C6 4.26485 0.079789 227.963 
I C77 C6 2.79199 0.100352 77.6788 
I C3 C6 0.48124 0.03984 5.81309 
I C73 C6 0.258308 0.001081 61.7478 
I C72 C6 0.302168 0.001273 71.7514 
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I C70 C6 3.50033 0.004328 2830.98 
I C45 C6 0.587723 0.034084 10.1344 
I C82 C6 0.584416 0.023647 14.4434 
I C38 C6 0.74922 0.129755 4.3261 
I C57 C6 0.898971 0.440411 1.83499 
I C90 C6 1.5339 0.053603 43.8936 
I C47 C6 0.655205 0.017476 24.5648 
I C78 C6 0.653166 0.008836 48.281 
I C59 C6 0.826347 0.085383 7.99746 
I C85 C6 1.269 0.043263 37.2225 
I C28 C6 1.40845 0.004804 412.893 
I C8 C6 1.1823 0.043473 32.1541 
I C58 C6 0.965664 0.435719 2.14016 
I C29 C6 0.754956 0.000155 3681.22 
I C49 C6 0.743288 6.27E-05 8817.25 
I C74 C6 1.30706 1.55E-07 1.10E+07 
I C24 C6 1.33116 4.97E-12 3.57E+11 
I C1 C6 0.979463 1.99E-05 48127.3 
Patients with complete response 
D C7 C6 2.27129 0.967299 5.33316 
D C52 C6 1.84394 0.902652 3.76681 
D C9 C6 0.63962 0.359906 1.13672 
D C56 C6 1.30813 0.718025 2.38321 
D C3 C6 0.692308 0.296584 1.61604 
D C24 C6 0.703125 0.301135 1.64174 
D C20 C6 1.22318 0.672741 2.22399 
D C80 C6 0.500818 0.033487 7.48997 
D C57 C6 1.41566 0.348882 5.74433 
D C58 C6 1.8024 0.153905 21.1081 
D C50 C6 0.65623 0.108926 3.95348 
D C91 C6 0.716851 0.169476 3.03215 
D C10 C6 1.35999 0.320729 5.76678 
D C42 C6 1.16473 0.52872 2.56581 
D C46 C6 0.937063 0.488282 1.79832 
D C30 C6 1.00589 0.510862 1.9806 
D C31 C6 0.990476 0.278457 3.52314 
I C71 C6 0.125615 0.024157 0.653186 
I C14 C6 0.355232 0.142912 0.882991 
I C51 C6 0.308476 0.108566 0.876492 
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I C37 C6 0.423695 0.17917 1.00194 
I C49 C6 0.370171 0.133258 1.02828 
I C13 C6 0.421213 0.1653 1.07333 
I C2 C6 0.39996 0.139544 1.14637 
I C48 C6 4.73667 0.456798 49.1159 
I C77 C6 1.79612 0.695196 4.64047 
I C3 C6 0.416939 0.080079 2.17083 
I C32 C6 1.91264 0.304896 11.9982 
I C58 C6 1.82484 0.325135 10.242 
I C72 C6 0.330886 0.010552 10.3761 
I C8 C6 0.77119 0.335864 1.77076 
I C45 C6 0.484484 0.02923 8.03039 
I C36 C6 0.586134 0.059741 5.75067 
I C73 C6 0.314546 0.001671 59.2029 
I C29 C6 0.478655 0.015518 14.7645 
I C90 C6 1.23117 0.381965 3.96835 
I C85 C6 1.21462 0.359969 4.09845 
I C23 C6 1.90383 0.032101 112.912 
I C27 C6 1.67256 0.029925 93.4827 
I C57 C6 1.39825 0.097942 19.9619 
I C21 C6 0.707792 0.037851 13.2352 
I C79 C6 1.29821 0.09855 17.1015 
I C53 C6 1.22318 0.069404 21.5575 
I C28 C6 0.799539 0.003736 171.118 
I C38 C6 1.18658 0.013187 106.768 
I C82 C6 0.602298 5.63E-09 6.44E+07 
I C1 C6 0.914652 0.011098 75.3794 
I C22 C6 1.06126 0.024267 46.4125 
I C74 C6 1.43536 1.42E-10 1.45E+10 
I C24 C6 1.50243 5.26E-14 4.29E+13 
I C78 C6 0.659352 2.53E-31 1.72E+30 
I C70 C6 1.00443 0.10781 9.35794 
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Supplementary Table 7: Common grade 3-4 hematological toxicities described by the 
included RCTs in the network meta-analysis, according to the grouping of 
chemotherapy treatments 
 
Anemia  Leukopenia  Neutropenia  Febrile neutropenia  Thrombocytopenia 
 
Treat
ment 
Sta
ge 
No 
of 
pati
ents 
(%) 
 Treat
ment 
Sta
ge 
No 
of 
patie
nts 
(%) 
 Treat
ment 
Sta
ge 
No 
of 
patie
nts 
(%) 
 Treat
ment 
Sta
ge 
No 
of 
patie
nts 
(%) 
 Treat
ment 
Sta
ge 
No 
of 
patie
nts 
(%) 
C68 ED 17 
(56.7
) 
 C51 LD
, 
ED 
51 
(100.
0) 
 C51 LD
, 
ED 
50 
(98.0
) 
 C7 ED 42 
(52.5
) 
 C52 ED 90 
(76.9
) 
C52 ED 59 
(50.4
) 
 C62 ED 66 
(84.6
) 
 C52 ED 113 
(96.6
) 
 C6 ED 31 
(37.8
) 
 C9 ED 77 
(56.2
) 
C69 ED 14 
(46.7
) 
 C63 ED 66 
(84.6
) 
 C70 ED 52 
(94.5
) 
 C70 ED 17 
(30.9
) 
 C64 ED 22 
(52.4
) 
C7 LD
, 
ED 
59 
(46.5
) 
 C85 ED 56 
(80.0
) 
 C9 ED 125 
(91.2
) 
 C59 ED 4 
(11.4
) 
 C27 ED 29 
(48.3
) 
C70 ED 25 
(45.5
) 
 C7 LD
, 
ED 
91 
(71.7
) 
 C53 ED 36 
(87.8
) 
 C50 ED 5 
(9.3) 
 C32 LD
, 
ED 
35 
(46.1
) 
C64 ED 18 
(42.9
) 
 C27 ED 42 
(70.0
) 
 C69 ED 26 
(86.7
) 
 C31 ED 26 
(5.3) 
 C63 ED 35 
(44.9
) 
C20 LD
, 
ED 
161 
(38.7
) 
 C8 LD
, 
ED 
162 
(67.2
) 
 C27 ED 49 
(81.7
) 
 C72 ED 7 
(1.4) 
 C20 LD
, 
ED 
185 
(44.5
) 
C32 ED 13 
(32.5
) 
 C53 ED 27 
(65.9
) 
 C6 LD
, 
ED 
1155 
(66.6
) 
     C18 LD
, 
ED 
29 
(41.4
) 
C85 ED 20 
(28.6
) 
 C64 ED 27 
(64.3
) 
 C28 ED 39 
(65.0
) 
     C85 ED 29 
(41.4
) 
C9 ED 38 
(27.7
) 
 C28 ED 36 
(60.0
) 
 C20 LD
, 
ED 
255 
(61.3
) 
     C65 ED 17 
(40.5
) 
C24 LD
, 
ED 
36 
(26.1
) 
 C90 LD
, 
ED 
63 
(58.9
) 
 C68 ED 17 
(56.7
) 
     C7 ED 28 
(35.0
) 
C67 ED 11 
(22.4
) 
 C69 ED 16 
(53.3
) 
 C31 ED 358 
(56.2
) 
     C59 ED 11 
(31.4
) 
C66 ED 11 
(21.6
) 
 C70 ED 29 
(52.7
) 
 C11 ED 102 
(55.7
) 
     C19 LD
, 
ED 
19 
(27.1
) 
C6 LD
, 
ED 
422 
(21.5
) 
 C68 ED 15 
(50.0
) 
 C12 ED 99 
(54.7
) 
     C79 ED 16 
(27.1
) 
C65 ED 9 
(21.4
) 
 C65 ED 20 
(47.6
) 
 C50 ED 154 
(46.2
) 
     C68 ED 8 
(26.7
) 
C53 ED 8 
(19.5
) 
 C60 LD
, 
ED 
38 
(44.7
) 
 C91 LD
, 
ED 
153 
(44.3
) 
     C70 ED 13 
(23.6
) 
C79 ED 10 
(16.9
) 
 C91 ED 114 
(40.3
) 
 C10 LD
, 
ED 
85 
(42.5
) 
     C12 ED 42 
(23.2
) 
C91 LD
, 
ED 
58 
(16.8
) 
 C3 LD
, 
ED 
87 
(36.9
) 
 C18 LD
, 
ED 
29 
(41.4
) 
     C67 ED 11 
(22.4
) 
C50 ED 52 
(15.6
) 
 C61 LD
, 
ED 
34 
(34.7
) 
 C42 LD
, 
ED 
47 
(38.8
) 
     C42 LD
, 
ED 
26 
(21.5
) 
C10 LD 29  C6 LD 495  C32 ED 15      C91 LD 74 
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, 
ED 
(14.5
) 
, 
ED 
(34.5
) 
(37.5
) 
, 
ED 
(21.4
) 
C59 ED 5 
(14.3
) 
 C24 LD
, 
ED 
70 
(33.2
) 
 C49 LD
, 
ED 
20 
(34.5
) 
     C31 LD
, 
ED 
138 
(20.5
) 
C42 LD
, 
ED 
17 
(14.0
) 
 C20 LD
, 
ED 
131 
(31.5
) 
 C8 LD
, 
ED 
17 
(28.3
) 
     C73 ED 8 
(20.0
) 
C27 ED 8 
(13,3
) 
 C59 ED 11 
(31.4
) 
 C59 ED 9 
(25.7
) 
     C11 ED 36 
(19.7
) 
C31 ED 84 
(13.2
) 
 C42 LD
, 
ED 
38 
(31.4
) 
 C7 LD
, 
ED 
12 
(25.5
) 
     C66 ED 10 
(19.6
) 
C11 ED 24 
(13.1
) 
 C66 ED 14 
(27.5
) 
 C19 LD
, 
ED 
17 
(24.3
) 
     C53 ED 8 
(19.5
) 
C18 LD
, 
ED 
9 
(12.9
) 
 C79 ED 15 
(25.4
) 
 C73 ED 7 
(17.5
) 
     C24 LD
, 
ED 
23 
(16.7
) 
C3 LD
, 
ED 
23 
(11.6
) 
 C67 ED 10 
(20.4
) 
 C5 LD
, 
ED 
5 
(11.9
) 
     C62 ED 12 
(15.4
) 
C12 ED 21 
(11.6
) 
 C31 LD
, 
ED 
125 
(19.7
) 
 C72 ED 52 
(10.6
) 
     C6 LD
, 
ED 
263 
(15.4
) 
C72 ED 53 
(10.8
) 
 C50 ED 43 
(12.9
) 
 C4 LD
, 
ED 
1 
(2.4) 
     C28 ED 9 
(15.0
) 
C19 LD
, 
ED 
7 
(10.0
) 
 C18 LD
, 
ED 
9 
(12.9
) 
         C8 LD
, 
ED 
23 
(12.7
) 
C28 ED 6 
(10.0
) 
 C32 LD
, 
ED 
4 
(11.1
) 
         C69 ED 3 
(10.0
) 
C8 ED 7 
(9.6) 
 C49 LD
, 
ED 
6 
(10.3
) 
         C72 ED 46 
(9.4) 
C73 ED 2 
(5.0) 
 C1 LD 4 
(9.3) 
         C61 LD
, 
ED 
7 
(7.1) 
    C38 ED 4 
(4.5) 
         C60 LD
, 
ED 
6 
(7.1) 
    C19 LD
, 
ED 
3 
(4.3) 
         C90 LD
, 
ED 
7 
(6.5) 
    C72 ED 18 
(4.0) 
         C50 ED 17 
(5.1) 
                C3 LD
, 
ED 
7 
(3.5) 
                C24 ED 2 
(2.7) 
                C38 ED 2 
(2.2) 
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Supplementary Table 8: Additional studies identified after the initial literature research 
Author, Year Description Journal Citation DOI Pub. Date Registry 
Belani 2016 Cisplatin + Etoposide, 
Cisplatin + Etoposide + Vismodegib, 
Cisplatin + Etoposide + Cixutumumab 
Cancer Cancer. 2016 Aug 
1;122(15):2371-8 
10.1002/cncr.30062 Aug-16 NCT00887159 
Fink 2012 Cisplatin + Etoposide, 
Cisplatin + Topotecan   
Journal of Thoracic Oncology J Thorac Oncol. 2012 
Sep;7(9):1432-9. 
10.1097/JTO.0b013e318260de75 Sep-12 NCT00320359 
Langer 2014 Carboplatin + Etoposide, 
Carboplatin + Etoposide + aBcl2 
Lung Cancer Lung Cancer. 2014 
Sep;85(3):420-8 
10.1016/j.lungcan.2014.05.003 Sep-14 NCT00682981 
Lu 2015 Carboplatin + Etoposide, 
Carboplatin + Etoposide + Endostatin 
Journal of Thoracic Oncology J Thorac Oncol. 
2015;10: 206–211) 
10.1097/JTO.0000000000000343 Jan-15 NCT00912392 
O’Brien 2011 Cisplatin + Etoposide, 
Amrubicin + Cisplatin, 
Amrubicin  
European Journal of Cancer Eur J Cancer. 2011 
Oct;47(15):2322-30. 
10.1016/j.ejca.2011.05.020 Oct-11 NCT00388960 
Oh 2016 Cisplatin + Etoposide, 
Cisplatin + Belotecan 
BMC Cancer BMC Cancer (2016) 
16:690 
10.1186/s12885-016-2741-z Aug-16 NCT00826644 
Owonikoko, 2014 Cisplatin + Etoposide + Topotecan, 
 Cisplatin + Etoposide + Irinotecan 
Cancer Chemother Pharmacol Cancer Chemother 
Pharmacol. 2014 
Jan;73(1):171-80 
10.1007/s00280-013-2338-z Jan-14 NCT00057837 
Reck 2013 Carboplatin + Paclitaxel, 
Carboplatin + Paclitaxel + Ipilimumab 
Annals of Oncology Annals of Oncology 24: 
75–83, 2013 
10.1093/annonc/mds213 Aug-12 NCT00527735 
Satoushi 2014 Cisplatin + Irinotecan, 
Cisplatin + Amrubicin 
Journal of Clinical Oncology J Clin Oncol. 2014 Apr 
20;32(12):1262-8 
10.1200/JCO.2013.53.5153 Apr-14 UMIN000000720 
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Sekine 2014 Carboplatin + Etoposide 
Amrubicin  
Clinical Lung Cancer Clin Lung Cancer. 2014 
Mar;15(2):96-102. 
10.1016/j.cllc.2013.11.006 Mar-15 NCT00286169 
Shi 2015 Cisplatin + Etoposide, 
Cisplatin + Irinotecan 
Thoracic Cancer Thoracic Cancer 6 
(2015) 785–791 
10.1111/1759-7714.12303 Jul-15 NCT02323737 
Spiegel 2011* Platin +  Etoposide, 
Platin +  Etoposide + Bevacizumab 
Journal of Clinical Oncology J Clin Oncol 29:2215-
2222 
  Jun-11 NCT00403403 
Sun 2016 Cisplatin + Etoposide, 
Cisplatin + Ambrubicin 
BMC Cancer BMC Cancer (2016) 
16:265 
10.1186/s12885-016-2301-6 Apr-16 NCT00660504 
Tiseo 2016 Cisplatin + Etoposide, 
Cisplatin + Etoposide + Bevacizumab 
1) Clinical Lung Cancer, 
2) ASCO 2016 
1) Clin Lung Cancer. 
2015 Jan;16(1):67-70,  
2) Journal of Clinical 
Oncology, 2016 ASCO 
Annual Meeting (June 3-
7, 2016). Vol 34, No 
15_suppl (May 20 
Supplement), 2016: 8513 
1) 10.1016/j.cllc.2014.09.001 Jun-16 2007-007949-13. 
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Supplementary Figures 
 
Supplementary Figure 1: Network of treatments for the outcome “patients with 
complete response”.  
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Supplementary Figure 2: Network of treatments for the outcome “patients with 
neutropenia”.  
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Supplementary Figure 3: Network of treatments for the outcome “patients with febrile 
neutropenia”.  
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Manuscripts 
 
Bakalos G, Miligos M, Doxani C et al. Assessing the relative effectiveness and tolerability of 
treatments in small cell lung cancer: a network meta-analysis. Cancer Epidemiol. 2013 
Oct;37(5):675-82 
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